Amsurg (AMSG) 10-K 26 Feb 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 26, 2014	Jun. 30, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'AMSURG CORP	'	'
Entity Central Index Key	'0000895930	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	32,487,151	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Well-known Seasoned Issuer	'Yes	'	'
Entity Public Float	'	'	$1,088,000,000

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$50,840	$46,398
Accounts receivable, net	105,072	96,752
Supplies inventory	18,414	18,406
Deferred income taxes	3,097	3,088
Prepaid and other current assets	33,602	27,537
Total current assets	211,025	192,181
Property and equipment, net	169,895	166,612
Investments in unconsolidated affiliates and long-term notes receivable	16,392	11,274
Goodwill	1,758,970	1,652,002
Intangible assets, net	21,662	22,517
Total assets	2,177,944	2,044,586
Liabilities and Equity	'	'
Current portion of long-term debt	20,844	17,407
Accounts payable	27,501	23,509
Accrued salaries and benefits	32,294	29,251
Other accrued liabilities	9,231	14,246
Total current liabilities	89,870	84,413
Long-term debt	583,298	620,705
Deferred income taxes	176,020	137,648
Other long-term liabilities	25,503	25,972
Commitments and contingencies	'	'
Noncontrolling interests - redeemable	177,697	175,382
Preferred stock, no par value, 5,000 shares authorized, no shares issued or outstanding	0	0
Equity:	'	'
Common stock, no par value, 70,000 shares authorized	185,873	183,867
Retained earnings	578,324	505,621
Total AmSurg Corp. equity	764,197	689,488
Noncontrolling interests - non-redeemable	361,359	310,978
Total equity	1,125,556	1,000,466
Total liabilities and equity	$2,177,944	$2,044,586

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Consolidated Balance Sheets	'	'
Net of allowance on accounts receivable	$27,862	$22,379
Preferred stock, par value	'	'
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	'	'
Preferred stock, shares outstanding	'	'
Common stock, par value	'	'
Common stock, shares authorized	70,000	70,000
Common stock, shares outstanding	32,353	31,941

Consolidated_Statements_Of_Ear

Consolidated Statements Of Earnings (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements Of Earnings	'	'	'
Revenues	$1,079,343	$923,182	$772,075
Operating expenses:	'	'	'
Salaries and benefits	333,190	290,063	238,738
Supply cost	157,771	131,055	101,364
Other operating expenses	222,677	193,025	168,347
Depreciation and amortization	33,028	29,850	25,645
Total operating expenses	746,666	643,993	534,094
Gain (loss) on deconsolidation	2,237	0	0
Equity in earnings of unconsolidated affiliates	3,151	1,564	613
Operating income	338,065	280,753	238,594
Interest expense	29,538	16,967	15,327
Earnings from continuing operations before income taxes	308,527	263,786	223,267
Income tax expense	49,754	42,364	34,973
Net earnings from continuing operations	258,773	221,422	188,294
Discontinued operations:	'	'	'
Earnings (loss) from operations of discontinued interests in surgery centers, net of income tax	169	2,196	3,363
Gain (loss) on disposal of discontinued interests in surgery centers, net of income tax	2,602	25	-1,543
Net earnings (loss) from discontinued operations	2,771	2,221	1,820
Net earnings	261,544	223,643	190,114
Less net earnings attributable to noncontrolling interests:	'	'	'
Net earnings from continuing operations	186,120	159,187	138,269
Net earnings (loss) from discontinued operations	2,721	1,893	1,848
Total net earnings attributable to noncontrolling interests	188,841	161,080	140,117
Net earnings (loss) attributable to AmSurg Corp. common shareholders	72,703	62,563	49,997
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'
Earnings from continuing operations, net of income tax	72,653	62,235	50,025
Discontinued operations, net of income tax	50	328	-28
Net earnings (loss) attributable to AmSurg Corp. common shareholders	$72,703	$62,563	$49,997
Earnings per share-basic:	'	'	'
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$2.32	$2.02	$1.64
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$0	$0.01	$0
Net earnings attributable to AmSurg Corp. common shareholders	$2.32	$2.03	$1.64
Earnings per share-diluted:	'	'	'
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$2.27	$1.97	$1.60
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders	$0	$0.01	$0
Net earnings attributable to AmSurg Corp. common shareholders	$2.28	$1.98	$1.60
Weighted average number of shares and share equivalents outstanding:	'	'	'
Basic	31,338	30,773	30,452
Diluted	31,954	31,608	31,211

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements Of Comprehensive Income	'	'	'	'	'	'	'	'	'	'	'
Net earnings	$71,168	$62,267	$65,836	$62,273	$59,394	$53,765	$55,545	$54,939	$261,544	$223,643	$190,114
Other comprehensive income, net of income tax:	'	'	'	'	'	'	'	'	'	'	'
Unrealized gain on interest rate swap, net of income tax	'	'	'	'	'	'	'	'	0	0	515
Comprehensive income, net of income tax	'	'	'	'	'	'	'	'	261,544	223,643	190,629
Less comprehensive income attributable to noncontrolling interests	'	'	'	'	'	'	'	'	188,841	161,080	140,117
Comprehensive income attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	$72,703	$62,563	$50,512

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Equity (USD $)	Total	Common Stock Including Additional Paid in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Loss [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable [Member]
Balance at Dec. 31, 2010	'	$171,522,000	$393,061,000	($515,000)	$12,799,000	$576,867,000	$147,740,000
Balance (in shares) at Dec. 31, 2010	'	31,040,000	'	'	'	'	'
Issuance of restricted common stock (in shares)	'	277,000	'	'	'	'	'
Cancellation of restricted common stock	'	-9,000	'	'	'	-9,000	'
Cancellation of restricted common stock (in shares)	'	-1,000	'	'	'	'	'
Stock options exercised	'	6,872,000	'	'	'	6,872,000	'
Stock options exercised (in shares)	374,350	374,000	'	'	'	'	'
Stock repurchased	'	-10,007,000	'	'	'	-10,007,000	'
Stock repurchased (in shares)	'	-406,000	'	'	'	'	'
Share-based compensation, value	6,178,000	6,178,000	'	'	'	6,178,000	'
Tax benefit related to exercise of stock options	'	649,000	'	'	'	649,000	'
Net earnings	190,114,000	'	49,997,000	'	10,181,000	60,178,000	129,936,000
Distributions to noncontrolling interests, net of capital contributions	'	'	'	'	-9,502,000	-9,502,000	-129,979,000
Purchase of noncontrolling interest, value	'	195,000	'	'	-817,000	-622,000	-788,000
Sale of noncontrolling interest, value	'	-1,702,000	'	'	439,000	-1,263,000	1,771,000
Acquisitions and other transactions impacting noncontrolling interests	'	'	'	'	122,276,000	122,276,000	21,390,000
Disposals and other transactions impacting noncontrolling interests	'	-511,000	'	'	-3,154,000	-3,665,000	566,000
Gain on interest rate swap, net of income tax expense	'	'	'	515,000	'	515,000	'
Balance at Dec. 31, 2011	'	173,187,000	443,058,000	0	132,222,000	748,467,000	170,636,000
Balance (in shares) at Dec. 31, 2011	'	31,284,000	'	'	'	'	'
Issuance of restricted common stock (in shares)	'	281,000	'	'	'	'	'
Cancellation of restricted common stock	'	0	'	'	'	0	'
Cancellation of restricted common stock (in shares)	'	-2,000	'	'	'	'	'
Stock options exercised	'	18,214,000	'	'	'	18,214,000	'
Stock options exercised (in shares)	841,599	842,000	'	'	'	'	'
Stock repurchased	'	-13,101,000	'	'	'	-13,101,000	'
Stock repurchased (in shares)	'	-464,000	'	'	'	'	'
Share-based compensation, value	6,692,000	6,692,000	'	'	'	6,692,000	'
Tax benefit related to exercise of stock options	'	1,834,000	'	'	'	1,834,000	'
Net earnings	223,643,000	'	62,563,000	'	26,303,000	88,866,000	134,777,000
Distributions to noncontrolling interests, net of capital contributions	'	'	'	'	-26,514,000	-26,514,000	-136,356,000
Purchase of noncontrolling interest, value	'	252,000	'	'	-421,000	-169,000	-81,000
Sale of noncontrolling interest, value	'	-2,794,000	'	'	4,352,000	1,558,000	0
Acquisitions and other transactions impacting noncontrolling interests	'	'	'	'	175,036,000	175,036,000	7,038,000
Disposals and other transactions impacting noncontrolling interests	'	-417,000	'	'	0	-417,000	-632,000
Balance at Dec. 31, 2012	1,000,466,000	183,867,000	505,621,000	0	310,978,000	1,000,466,000	175,382,000
Balance (in shares) at Dec. 31, 2012	'	31,941,000	'	'	'	'	'
Issuance of restricted common stock (in shares)	'	292,000	'	'	'	'	'
Cancellation of restricted common stock (in shares)	'	-16,000	'	'	'	'	'
Stock options exercised	'	33,349,000	'	'	'	33,349,000	'
Stock options exercised (in shares)	1,392,366	1,393,000	'	'	'	'	'
Stock repurchased	'	-45,964,000	'	'	'	-45,964,000	'
Stock repurchased (in shares)	'	-1,257,000	'	'	'	'	'
Share-based compensation, value	8,321,000	8,321,000	'	'	'	8,321,000	'
Tax benefit related to exercise of stock options	'	7,247,000	'	'	'	7,247,000	'
Net earnings	261,544,000	'	72,703,000	'	49,789,000	122,492,000	139,052,000
Distributions to noncontrolling interests, net of capital contributions	'	'	'	'	-49,533,000	-49,533,000	-134,298,000
Purchase of noncontrolling interest, value	'	679,000	'	'	-1,926,000	-1,247,000	-319,000
Sale of noncontrolling interest, value	'	-1,626,000	'	'	2,327,000	701,000	852,000
Acquisitions and other transactions impacting noncontrolling interests	'	'	'	'	50,041,000	50,041,000	0
Disposals and other transactions impacting noncontrolling interests	'	0	'	'	-317,000	-317,000	-2,972,000
Balance at Dec. 31, 2013	$1,125,556,000	$185,873,000	$578,324,000	$0	$361,359,000	$1,125,556,000	$177,697,000
Balance (in shares) at Dec. 31, 2013	'	32,353,000	'	'	'	'	'

Consolidated_Statements_Of_Cha1

Consolidated Statements Of Changes In Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2011
Consolidated Statements Of Changes In Equity	'
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	$332

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net earnings (loss)	$261,544	$223,643	$190,114
Adjustments to reconcile net earnings to net cash flows provided by operating activities:	'	'	'
Depreciation and amortization	33,028	29,850	25,645
Net (gain) loss on sale of long-lived assets	-1,468	-1,065	-1,518
(Gain) loss on deconsolidation	-2,237	0	0
Share-based compensation	8,321	6,692	6,178
Excess tax benefit from share-based compensation	-7,247	-1,784	-977
Deferred income taxes	38,363	24,558	23,623
Equity in earnings of unconsolidated affiliates, net	-3,151	-1,564	-613
Increase (decrease) in cash and cash equivalents, net of effects of acquisitions and dispositions, due to changes in:	'	'	'
Accounts receivable, net	-1,297	8,061	-2,122
Supplies inventory	132	110	168
Prepaid and other current assets	-5,308	-4,651	838
Accounts payable	441	579	-2,205
Accrued expenses and other liabilities	6,693	7,550	2,329
Other, net	5,010	3,673	1,963
Net cash flows provided by operating activities	332,824	295,652	243,423
Cash flows from investing activities:	'	'	'
Acquisition of interests in surgery centers and related transactions	-73,594	-277,388	-239,223
Acquisition of property and equipment	-28,856	-28,864	-22,170
Proceeds from sale of interests in surgery centers	3,553	7,309	7,026
Other	159	0	0
Net cash flows used in investing activities	-98,738	-298,943	-254,367
Cash flows from financing activities:	'	'	'
Proceeds from long-term borrowings	162,204	565,566	288,869
Repayment on long-term borrowings	-202,083	-394,164	-129,107
Distributions to noncontrolling interests	-184,149	-162,941	-138,724
Proceeds from issuance of common stock upon exercise of stock options	33,349	18,214	6,872
Repurchase of common stock	-45,964	-13,101	-10,007
Capital contributions and ownership transactions by noncontrolling interests	1,074	1,595	660
Excess tax benefit from share-based compensation	7,247	1,784	977
Financing cost incurred	-1,322	-7,982	-2,025
Net cash flows provided by (used in) financing activities	-229,644	8,971	17,515
Net increase in cash and cash equivalents	4,442	5,680	6,571
Cash and cash equivalents, beginning of year	46,398	40,718	34,147
Cash and cash equivalents, end of year	$50,840	$46,398	$40,718

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	1. Summary of Significant Accounting Policies
	a.       Principles of Consolidation
	AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”). The Company does not have an ownership interest in a limited partnership or LLC greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in six limited partnerships and LLCs, three of which it consolidates as the Company has substantive participation rights and three of which it does not consolidate as the Company's rights are limited to protective rights only. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated limited partnerships and LLCs. Consolidation of such limited partnerships and LLCs is necessary as the Company's wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the limited partnerships and LLCs, and have control of the entities. The responsibilities of the Company's noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. All limited partnerships and LLCs and noncontrolling partners are referred to herein as (“partnerships”) and (“partners”), respectively.
	Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the consolidated statements of cash flows.
	As further described in note 14, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company's partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2013, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company's equity and are classified as noncontrolling interests – redeemable on the Company's consolidated balance sheets.
	Center profits and losses of consolidated entities are allocated to the Company's partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company's center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company's consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense. In addition, distributions from the partnerships are made to both the Company's wholly owned subsidiaries and the partners on a pre-tax basis.
	Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates and long-term notes receivable in the accompanying consolidated balance sheets. The Company's share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings and comprehensive income. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
	Each of the Company's centers have similar economic characteristics and are aggregated into a single component. The Company operates this component as one reportable business segment, the ownership and operation of ambulatory surgery centers.
	b.       Cash and Cash Equivalents
	Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased.
	c.       Accounts Receivable
	The determination of contractual and bad debt allowances constitutes a significant estimate. Some of the factors considered by management in determining the amount of such allowances are the historical trends of the centers' cash collections and contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics. Accordingly, net accounts receivable at December 31, 2013 and 2012 reflect allowances for contractual adjustments of $289,937,000 and $216,363,000, respectively, and allowance for bad debt expense of $27,862,000 and $22,379,000, respectively.
	d.       Supplies Inventory
	Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.
	e.       Prepaid and Other Current Assets
	At December 31, 2013, prepaid and other current assets were comprised of short-term investments of $13,313,000, other prepaid expenses of $7,099,000, prepaid insurance expense of $5,631,000, other current receivables of $6,126,000 and other current assets of $1,433,000. At December 31, 2012, prepaid and other current assets were comprised of short-term investments of $8,804,000, other prepaid expenses of $6,462,000, prepaid insurance expense of $4,963,000, other current receivables of $5,926,000 and other current assets of $1,382,000.
	f.       Property and Equipment, net
	Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment and software and software development costs is recognized over useful lives of three to ten years.
	g.       Goodwill
	The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered. Goodwill is to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. The Company has determined that it has one operating, as well as one reportable, segment. For impairment testing purposes, the centers qualify as components of that operating segment. Because they have similar economic characteristics, the components are aggregated and deemed a single reporting unit. The Company completed its annual impairment test as of December 31, 2013, and determined that goodwill was not impaired.
	h.       Intangible Assets
	Intangible assets consist primarily of deferred financing costs of the Company and certain amortizable and non-amortizable non-compete and customer agreements. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense, respectively.
	i.       Other Long-Term Liabilities
	At December 31, 2013, other long-term liabilities are comprised of deferred rent of $14,637,000, tax-effected unrecognized benefits of $6,888,000 (see note 1(k)), unfavorable lease liability of $3,034,000 and other long-term liabilities of $944,000. At December 31, 2012, other long-term liabilities are comprised of deferred rent of $12,134,000, tax-effected unrecognized benefits of $10,113,000 (see note 1(k)), unfavorable lease liability of $3,559,000 and other long-term liabilities of $166,000.
	j.       Revenue Recognition
	Center revenues consist of billing for the use of the centers' facilities directly to the patient or third-party payor and, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by our centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians' surgical services, which are billed separately by the physicians to the patient or third-party payor.
	Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2013, 2012 and 2011, the Company derived approximately 25%, 27% and 29%, respectively, of its revenues from government healthcare programs, primarily Medicare, and managed Medicare programs. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.
	k.       Operating Expenses
	Substantially all of the Company's operating expenses relate to the cost of revenues and the delivery of care at the Company's surgery centers. Such costs primarily include the surgery centers' clinical and administrative salaries and benefits, supply cost, rent and other variable expenses, such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense. Bad debt expense for continuing operations was approximately $21,947,000, $20,005,000 and $18,230,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	l.       Income Taxes
	The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company's policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.
	The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2010.
	m.       Earnings Per Share
	Basic earnings per share is computed by dividing net earnings attributable to AmSurg Corp. common shareholders by the combined weighted average number of common shares, while diluted earnings per share is computed by dividing net earnings attributable to AmSurg Corp. common shareholders by the weighted average number of such common shares and dilutive share equivalents.
	n.       Share-Based Compensation
	Transactions in which the Company receives employee and non-employee services in exchange for the Company's equity instruments or liabilities that are based on the fair value of the Company's equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense.
	Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company's net operating cash flows and increasing its financing cash flows by $7,247,000, $1,784,000 and $977,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to disclose or pay any cash dividends in the foreseeable future.
	o.       Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	p.       Reclassifications
	Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 3.

Acquisitions_and_Investments_i

Acquisitions and Investments in Unconsolidated Affiliates	12 Months Ended
	Dec. 31, 2013
Acquisitions and Investments in Unconsolidated Affiliates	'
Acquisitions and Investments in Unconsolidated Affiliates	'
	2. Acquisitions and Investments in Unconsolidated Affiliates
	As a significant part of its growth strategy, the Company primarily acquires controlling interests in centers. The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.
	During 2013 and 2012, the Company, through a wholly owned subsidiary, acquired a controlling interest in five centers and 17 centers, respectively. One of the centers acquired during 2012 was immediately merged into an existing center.
	The aggregate amount paid for the centers acquired and for settlement of purchase price payable obligations during December 31, 2013 and 2012 was approximately $73,594,000 and $277,388,000, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company's revolving credit facility. The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers' favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company's business model.
	In conjunction with the Company's acquisition of 17 centers from National Surgical Care, Inc. (“NSC”) on September 1, 2011, the Company agreed to pay as additional consideration an amount up to $7,500,000 based on a multiple of the excess earnings over the targeted earnings of the acquired centers, if any, from the period of January 1, 2012 to December 31, 2012. At December 31, 2012, the Company had a contingent purchase price obligation of $2,744,000, which was paid during 2013 as final settlement of the additional consideration due in accordance with the purchase agreement.
	The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed during 2013 and 2012, including post acquisition date adjustments recorded to finalize purchase price allocations, are as follows (in thousands):
			2013			2012
	Accounts receivable		$	4,011		$	11,572
	Supplies inventory, prepaid and other current assets			2,014			4,750
	Property and equipment			6,894			23,546
	Goodwill			116,243			429,504
	Other intangible assets			-			800
	Accounts payable			-2,214			-3,199
	Other accrued liabilities			-532			-2,387
	Long-term debt			-3,028			-6,954
	Other long-term liabilities			-254			-
		Total fair value		123,134			457,632
		Less: Fair value attributable to noncontrolling interests		49,792			182,073
		Acquisition date fair value of total consideration transferred	$	73,342		$	275,559
	Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market. Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests in centers. Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability. The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. During 2013 and 2012, approximately $70,147,000 and $260,547,000, respectively, of goodwill recorded was deductible for tax purposes. Associated with the transactions discussed above, the Company incurred and expensed in other operating expenses in the accompanying consolidated statements of earnings approximately $300,000 and $700,000 in acquisition related costs during 2013 and 2012, respectively.
	Revenues and net earnings included in the years ended December 31, 2013 and 2012 associated with these acquisitions are as follows (in thousands):
			2013			2012
	Revenues		$	15,616		$	11,247
	Net earnings			4,596			3,441
	Less: Net earnings attributable to noncontrolling interests			2,603			1,977
		Net earnings attributable to AmSurg Corp. common shareholders	$	1,993		$	1,464
	The unaudited consolidated pro forma results for the years ended December 31, 2013 and 2012, assuming all 2013 acquisitions had been consummated on January 1, 2012 and all 2012 acquisitions had been consummated on January 1, 2011, are as follows (in thousands, except per share data):
					2013			2012
	Revenues				$	1,108,686		$	1,116,214
	Net earnings					269,903			261,251
	Amounts attributable to AmSurg Corp. common shareholders:
		Net earnings from continuing operations				75,411			76,893
		Net earnings				75,461			77,221
		Net earnings from continuing operations per common share:
			Basic		$	2.41		$	2.5
			Diluted		$	2.36		$	2.43
		Net earnings:
			Basic		$	2.41		$	2.51
			Diluted		$	2.36		$	2.44
		Weighted average number of shares and share equivalents:
			Basic			31,338			30,773
			Diluted			31,954			31,608
	During 2013, the Company entered into a transaction whereby it contributed cash plus a controlling interest in one center in exchange for a noncontrolling interest in an entity that, after the completion of the transaction, controls the contributed center and one additional center. Management of the Company believes this structure provides both economies of scale and potential future growth opportunities in the market. As a result of the transaction, the Company recorded in the accompanying consolidated balance sheets the fair value of the noncontrolling interest in the entity which now controls the contributed centers of approximately $5,201,000 as a component of investments in unconsolidated affiliates and long term notes receivable. The Company also recognized a gain on deconsolidation in the accompanying consolidated statements of earnings and comprehensive income of approximately $2,237,000. Such gain was determined based on the difference between the fair value of the Company's noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed center immediately prior to the transaction. The fair value of the Company's noncontrolling interest was based on various estimates of the expected future earnings under likely scenarios which were weighted by the probability of each outcome using a range of expected probability of 5% to 30%. Subsequent to the completion of this transaction, the center contributed by the Company was merged into the acquired center.

Dispositions

Dispositions	12 Months Ended
	Dec. 31, 2013
Dispositions	'
Dispositions	'
	3. Dispositions
	The Company initiated the dispositions of certain of its centers primarily due to management's assessment of the limited growth opportunities at these centers and as a result of certain market driven strategies. Results of operations of the centers discontinued for the years ended December 31, 2013, 2012 and 2011, are as follows (in thousands):
		2013		2012		2011
	Cash proceeds from disposal	$	3,553	$	7,309	$	7,026
	Net earnings from discontinued operations		2,771		2,221		1,820
	Net gain (loss) from discontinued operations attributable to AmSurg Corp.		50		328		-28
	The results of operations of discontinued centers have been classified as discontinued operations in all periods presented. Results of operations of the combined discontinued surgery centers for the years ended December 31, 2013, 2012 and 2011 are as follows (in thousands):
		2013		2012		2011
	Revenues	$	3,224	$	10,975	$	18,814
	Earnings before income taxes		227		2,724		4,318
	Net earnings		169		2,196		3,363

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment	'
Property, Plant and Equipment	'
	4. Property and Equipment
	Property and equipment at December 31, 2013 and 2012 were as follows (in thousands):
			2013		2012
	Building and improvements		$	161,805	$	151,270
	Movable equipment and software			228,212		208,541
	Construction in progress			2,321		2,313
				392,338		362,124
	Less accumulated depreciation			-222,443		-195,512
		Property and equipment, net	$	169,895	$	166,612
	The Company capitalized interest in the amount of $24,000, $43,000 and $85,000 for the years ended December 31, 2013, 2012 and 2011, respectively. At December 31, 2013, the Company and its partnerships had unfunded construction and equipment purchases of approximately $953,000 in order to complete construction in progress. Depreciation expense for continuing and discontinued operations for the years ended December 31, 2013, 2012 and 2011 was $32,974,000, $30,072,000 and $26,068,000, respectively.

Goodwill_And_Intangible_Assets

Goodwill And Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets	'
Goodwill And Intangible Assets	'
	5. Goodwill and Intangible Assets
	The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012 are as follows (in thousands):
			2013		2012
	Balance, beginning of period		$	1,652,002	$	1,229,298
	Goodwill acquired, including post acquisition adjustments			112,951		429,504
	Goodwill disposed, including impact of deconsolidation transaction			-5,983		-6,800
		Balance, end of period	$	1,758,970	$	1,652,002
	Amortizable intangible assets at December 31, 2013 and 2012 consisted of the following (in thousands):
					2013						2012
					Gross						Gross
					Carrying		Accumulated				Carrying		Accumulated
					Amount		Amortization		Net		Amount		Amortization		Net
	Deferred financing cost				$	15,814	$	-4,953	$	10,861	$	14,523	$	-3,029	$	11,494
	Agreements, contracts and other intangible assets					3,448		-2,472		976		3,448		-2,250		1,198
				Total amortizable intangible assets	$	19,262	$	-7,425	$	11,837	$	17,971	$	-5,279	$	12,692
	Amortization of intangible assets for the years ended December 31, 2013, 2012 and 2011 was $2,178,000, $1,415,000 and $1,472,000, respectively. During 2012, deferred financing costs increased approximately $6,200,000 related to the issuance of the senior unsecured notes. Estimated amortization of intangible assets for the five years and thereafter subsequent to December 31, 2013, with a weighted average amortization period of 5.7 years, is $2,243,000, $2,242,000, $2,242,000, $1,988,000, $1,424,000 and $1,698,000.
	At December 31, 2013 and 2012, other non-amortizable intangible assets related to restrictive covenant arrangements were $9,825,000, respectively.

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2013
Long-Term Debt	'
Long-Term Debt	'
	6. Long-term Debt
	Long-term debt at December 31, 2013 and 2012 was comprised of the following (in thousands):
				2013		2012
	Revolving credit agreement (average rate of 2.1%)			$	252,500	$	279,780
	Senior Unsecured Notes due 2020 (5.625%)				250,000		250,000
	Senior Secured Notes due 2020 (8.04%)				69,643		75,000
	Other debt at an average rate of 3.6%, due through 2025				21,149		21,350
	Capitalized lease arrangements at an average rate of 5.3%, due through 2026				10,850		11,982
					604,142		638,112
	Less current portion				20,844		17,407
		Long-term debt		$	583,298	$	620,705
	Principal payments required on the Company's long-term debt and capital leases in the five years and thereafter subsequent to December 31, 2013 are $20,844,000, $17,751,000, $14,903,000, $13,422,000, $265,037,000, and $272,185,000.
	a.       Credit Facility
	On June 29, 2012, the Company amended its revolving credit agreement to increase the borrowing capacity and adjust the interest rate spreads. On November 7, 2012, the Company further amended its revolving credit agreement to allow for the Company's issuance of the 5.625% senior unsecured notes (discussed below), which resulted in certain adjustments to the existing covenants. On June 14, 2013, the Company amended its revolving credit agreement to adjust the interest rate spreads and extend the maturity date by one year. The revolving credit agreement, as amended, permits the Company to borrow up to $475,000,000 at an interest rate equal to, at the Company's option, the base rate plus 0.25% to 1.00% or LIBOR plus 1.25% to 2.00%, or a combination thereof; provides for a fee of 0.25% to 0.40% of unused commitments; and contains certain covenants relating to the ratio of debt to operating performance measurements, interest coverage ratios and minimum net worth. Borrowings under the revolving credit agreement mature in June 2018 and are secured by a pledge of the stock of the Company's wholly-owned subsidiaries and the Company's partnership and membership interests in the limited partnerships and limited liability companies. The Company was in compliance with the covenants contained in the revolving credit agreement at December 31, 2013.
	b.       Senior Unsecured Notes
	On November 20, 2012, the Company completed a private offering of $250,000,000 aggregate principal amount of 5.625% senior unsecured notes due 2020 (the “Senior Unsecured Notes”). The net proceeds from the issuance of the Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company's existing revolving credit agreement. In connection with the issuance of the Senior Unsecured Notes, the Company entered into a registration rights agreement, dated November 20, 2012 (the “Registration Rights Agreement”). On May 2, 2013, under the terms of the Registration Rights Agreement, the Company commenced an offer to exchange the outstanding Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended. The exchange offer was completed on May 31, 2013 and all holders of the Senior Unsecured Notes participated in the exchange. The Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.
	Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after November 30, 2015, the Company may redeem the Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:
	Period		Redemption Price
	2015		104.22%
	2016		102.81%
	2017		101.41%
	2018 and thereafter		100.00%
	The Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company's ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. The Company was in compliance with the covenants contained in the indenture relating to the Senior Unsecured Notes at December 31, 2013.
	c.       Senior Secured Notes
	The Company issued $75,000,000 principal amount of senior secured notes (the “Senior Secured Notes”) on May 28, 2010 pursuant to a note purchase agreement. The Senior Secured Notes mature on May 28, 2020. The Senior Secured Notes, which were originally issued with a stated interest rate of 6.04%, were amended on November 7, 2012 to allow for the Company's issuance of the Senior Unsecured Notes, which resulted in an increase in the annual interest rate of 2.00% to 8.04%, and included certain other adjustments to the existing covenants. The Senior Secured Notes are pari passu with the indebtedness under the Company's revolving credit agreement and the Senior Unsecured Notes and principal payments began in August 2013. The note purchase agreement governing the Senior Secured Notes contains covenants similar to the covenants in the revolving credit agreement and includes a make whole provision in the event of any prepayment of principle. The Company was in compliance with the covenants contained in the note purchase agreement relating to the Senior Secured Notes at December 31, 2013.
	d.       Other Debt
	Certain partnerships included in the Company's consolidated financial statements have loans with local lending institutions, included above in other debt, which are collateralized by certain assets of the centers with a book value of approximately $74,150,000. The Company and the partners have guaranteed payment of the loans in proportion to the relative partnership interests.

Derivative_Instruments

Derivative Instruments	12 Months Ended
	Dec. 31, 2013
Derivative Instruments	'
Derivative Instruments	'
	7. Derivative Instruments
	The Company entered into an interest rate swap agreement in April 2006, the objective of which was to hedge exposure to the variability of the future expected cash flows attributable to the variable interest rate of a portion of the Company's outstanding balance under its revolving credit agreement. The interest rate swap matured in April 2011. Prior to April 2011, the interest rate swap had a notional amount of $50,000,000. The Company paid to the counterparty a fixed rate of 5.365% of the notional amount of the interest rate swap and received a floating rate from the counterparty based on LIBOR. In the opinion of management and as permitted by Accounting Standards Codification Topic 815, Derivatives and Hedging (“ASC 815”), the interest rate swap (as a cash flow hedge) was a fully effective hedge. Payments or receipts of cash under the interest rate swap were shown as a part of operating cash flows, consistent with the interest expense incurred pursuant to the revolving credit agreement. An increase in the fair value of the interest rate swap, net of tax, of $515,000 was included in other comprehensive income in the year ended December 31, 2011.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements	'
Fair Value Measurements	'
	8. Fair Value Measurements
	The fair value of a financial instrument is the amount at which the instrument could be exchanged in an orderly transaction between market participants to sell the asset or transfer the liability. The inputs used by the Company to measure fair value are classified into the following fair value hierarchy:
	Level 1: Quoted prices in active markets for identical assets or liabilities.
	Level 2: Inputs other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
	Level 3: Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.
	In determining the fair value of assets and liabilities that are measured on a recurring basis at December 31, 2013 and 2012, with the exception of the contingent purchase price payable, the Company utilized Level 2 inputs to perform such measurements methods which were commensurate with the market approach. The Company utilized Level 3 inputs, which utilizes unobservable data, to measure the fair value of the contingent purchase price payable (in thousands):
			2013		2012
	Assets:
		Supplemental executive retirement savings plan investments - Level 2	$	13,313	$	8,804
	Liabilities:
		Contingent purchase price payable - Level 3 (see note 2)	$	-	$	2,744
	The fair value of the supplemental executive and director retirement savings plan investments, which are included in prepaid and other current assets, was determined using the calculated net asset values obtained from the plan administrator and observable inputs of similar public mutual fund investments. The fair value of the contingent purchase price payable related to the centers acquired from NSC as of December 31, 2012, was determined utilizing the actual earnings of those centers during the earnout period, January 1, 2012 to December 31, 2012, in accordance with the purchase agreement. During the year ended December 31, 2013, the Company paid $2,744,000 as final settlement of the contingent purchase price payable using its revolving credit facility. There were no transfers to or from Levels 1 and 2 during the year ended December 31, 2013.
	Cash and cash equivalents, receivables and payables are reflected in the financial statements at cost, which approximates fair value. The fair value of fixed rate long-term debt, with a carrying value of $348,958,000, was approximately $364,349,000 at December 31, 2013. The fair value of variable-rate long-term debt approximates its carrying value of $255,184,000 at December 31, 2013. The fair value of fixed rate long-term debt, with a carrying value of $354,105,000, was approximately $379,036,000 at December 31, 2012. The fair value of variable-rate long-term debt approximates its carrying value of $284,007,000 at December 31, 2012.With the exception of the Company's Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders. The fair value of the Company's Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

Leases

Leases	12 Months Ended
	Dec. 31, 2013
Leases	'
Leases	'
	9. Leases
	The Company has entered into various building and equipment capital and operating leases for its surgery centers in operation and under development and for office space, expiring at various dates through 2033. Future minimum lease payments, including payments during expected renewal option periods, at December 31, 2013 were as follows (in thousands):
			Capitalized		Operating
	Year Ended December 31,		Equipment Leases		Leases
	2014		$	2,040	$	47,704
	2015			1,673		46,557
	2016			1,404		45,772
	2017			1,184		45,174
	2018			1,000		43,718
	Thereafter			7,003		354,087
		Total minimum rentals		14,304	$	583,012
	Less amounts representing interest at rates ranging from 2.9% to 11.8%			3,454
		Capital lease obligations	$	10,850
	At December 31, 2013, buildings and equipment with a cost of approximately $13,950,000 and accumulated depreciation of approximately $3,635,000 were held under capital leases. The Company and the partners in the partnerships have guaranteed payment of certain of these leases. Rental expense for continuing and discontinued operations for operating leases for the years ended December 31, 2013, 2012 and 2011 was approximately $52,641,000, $47,278,000 and $42,413,000, respectively.

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Shareholders' Equity	'
Shareholders' Equity	'
	10. Shareholders' Equity
	a.       Common Stock
	On April 24, 2012, the Board of Directors authorized a stock purchase program for up to $40,000,000 of the Company's shares of common stock. The Company completed this repurchase program in August 2013. On August 9, 2013, the Board of Directors authorized a stock purchase program for up to $40,000,000 of the Company's shares of common stock to be purchased through February 9, 2015. As of December 31, 2013, there was approximately $27,100,000 available under the stock repurchase program.
	During the year ended 2013, the Company purchased 1,154,378 shares of the Company's common stock for approximately $42,652,000, at an average price of $36.93 per share, in order to mitigate the dilutive effect of shares issued upon the exercise of stock options pursuant to the Company's stock incentive plans. During the year ended 2012, the Company purchased 415,084 shares of the Company's common stock for approximately $11,838,000, at an average price of $28.50 per share. In addition, during 2013 and 2012, the Company repurchased 102,252 shares and 48,139 shares, respectively, of common stock for approximately $3,312,000 and $1,263,000, respectively, to cover payroll withholding taxes in connection with the vesting of restricted stock awards in accordance with the restricted stock agreements.
	b.       Stock Incentive Plans
	In May 2006, the Company adopted the AmSurg Corp. 2006 Stock Incentive Plan. The Company also has options outstanding under the AmSurg Corp. 1997 Stock Incentive Plan, under which no additional awards may be granted. Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock. At December 31, 2013, 2,760,250 shares were authorized for grant under the 2006 Stock Incentive Plan and 895,822 shares were available for future equity grants, including 733,704 shares available for issuance as restricted stock. Restricted stock granted to outside directors prior to 2012 vested over a two year period and restricted stock granted to outside directors in 2012 and 2013 vest over a one year period. Shares held by outside directors are subject to certain holding restrictions. Restricted stock granted to employees during 2010 and thereafter vests over four years in three equal installments beginning on the second anniversary of the date of grant. Restricted stock granted to employees prior to 2010 vests at the end of four years from the date of grant. Shares held by the Company's senior management are subject to certain holding restrictions. The fair value of restricted stock is determined based on the closing bid price of the Company's common stock on the grant date.
	No options have been issued subsequent to 2008 and all outstanding options are fully vested. Options were granted at market value on the date of the grant and vested over four years. Outstanding options have a term of ten years from the date of grant.
	Other information pertaining to share-based activity for the years ended December 31, 2013, 2012 and 2011 was as follows (in thousands):
		2013			2012			2011
	Share-based compensation expense	$	8,321		$	6,692		$	6,178
	Fair value of shares vested		11,742			6,425			7,356
	Cash received from option exercises		33,349			18,214			6,872
	Tax benefit from option exercises		7,247			1,784			977
	As of December 31, 2013, the Company had total unrecognized compensation cost of approximately $7,426,000 related to non-vested awards, which the Company expects to recognize through 2017 and over a weighted-average period of 1.0 year.
	Average outstanding share-based awards to purchase approximately 20,000 and 923,000 shares of common stock that had an exercise price in excess of the average market price of the common stock during the years ended December 31, 2012 and 2011, respectively, were not included in the calculation of diluted securities under the treasury method for purposes of determining diluted earnings per share due to their anti-dilutive impact. During the year ended December 31, 2013, there were no options that were anti-dilutive.
	A summary of the status of and changes for non-vested restricted shares for the three years ended December 31, 2013, is as follows:
							Weighted
					Number		Average
					of		Grant
					Shares		Price
	Non-vested shares at January 1, 2011				664,909		$	22.16
		Shares granted			276,869			21.78
		Shares vested			-208,949			23.11
		Shares forfeited			-417			24.75
	Non-vested shares at December 31, 2011				732,412		$	21.91
		Shares granted			281,429			26.78
		Shares vested			-183,019			25.98
		Shares forfeited			-2,136			26.26
	Non-vested shares at December 31, 2012				828,686		$	22.5
		Shares granted			291,863			31.66
		Shares vested			-360,337			21.55
		Shares forfeited			-16,343			23.11
	Non-vested shares at December 31, 2013				743,869		$	26.54
	A summary of stock option activity for the three years ended December 31, 2013 is summarized as follows:
									Weighted
									Average
						Weighted			Remaining
				Number		Average			Contractual
				of		Exercise			Term
				Shares		Price			(in years)
	Outstanding at January 1, 2011			2,901,989		$	22.49		4.5
		Options exercised with total intrinsic value of $2,482,000		-374,350			18.36
		Options terminated		-17,585			25.42
	Outstanding at December 31, 2011			2,510,054		$	23.09		3.4
		Options exercised with total intrinsic value of $6,287,000		-841,599			21.64
		Options terminated		-5,625			21.85
	Outstanding at December 31, 2012			1,662,830		$	23.82		2.9
		Options exercised with total intrinsic value of $33,349,000		-1,392,366			23.95
	Outstanding at December 31, 2013 with aggregate intrinsic value of $6,156,000			270,464		$	23.16		2.5
	Vested or expected to vest at December 31, 2013 with total intrinsic value of $6,156,000			270,464		$	23.16		2.5
	Exercisable at December 31, 2013 with total intrinsic value of $6,156,000			270,464		$	23.16		2.5
	The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at December 31, 2013 exercised their options at the Company's closing stock price on December 31, 2013.
	c. Earnings per Share
	The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):
										Per
					Earnings			Shares		Share
					(Numerator)			(Denominator)		Amount
	For the year ended December 31, 2013:
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (basic)		$	72,653		31,338		$	2.32
		Effect of dilutive securities options and non-vested shares				-		616
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (diluted)		$	72,653		31,954		$	2.27
	Net earnings attributable to AmSurg Corp. per common share (basic)			$	72,703		31,338		$	2.32
	Effect of dilutive securities options and non-vested shares				-		616
	Net earnings attributable to AmSurg Corp. per common share (diluted)			$	72,703		31,954		$	2.28
For the year ended December 31, 2012:
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (basic)		$	62,235		30,773		$	2.02
	Effect of dilutive securities options and non-vested shares				-		835
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (diluted)		$	62,235		31,608		$	1.97
	Net earnings attributable to AmSurg Corp. per common share (basic)			$	62,563		30,773		$	2.03
	Effect of dilutive securities options and non-vested shares				-		835
	Net earnings attributable to AmSurg Corp. per common share (diluted)			$	62,563		31,608		$	1.98
For the year ended December 31, 2011:
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (basic)		$	50,025		30,452		$	1.64
	Effect of dilutive securities options and non-vested shares				-		759
	Net earnings from continuing operations attributable to
		AmSurg Corp. per common share (diluted)		$	50,025		31,211		$	1.6
	Net earnings attributable to AmSurg Corp. per common share (basic)			$	49,997		30,452		$	1.64
	Effect of dilutive securities options and non-vested shares				-		759
	Net earnings attributable to AmSurg Corp. per common share (diluted)			$	49,997		31,211		$	1.6

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Income Taxes	'
	11. Income Taxes
	Total income taxes expense (benefit) for the years ended December 31, 2013, 2012 and 2011 was included within the following sections of the consolidated financial statements as follows (in thousands):
			2013			2012			2011
	Income from continuing operations		$	49,754		$	42,364		$	34,973
	Discontinued operations			-1,091			1,574			3,032
	Shareholders’ equity			-7,381			-1,581			-649
	Other comprehensive income			-			-			332
		Total	$	41,282		$	42,357		$	37,688
	Income tax expense from continuing operations for the years ended December 31, 2013, 2012 and 2011 was comprised of the following (in thousands):
			2013			2012			2011
	Current:
		Federal	$	8,437		$	15,326		$	11,671
		State		3,724			4,974			3,541
	Deferred:
		Federal		31,909			18,488			17,502
		State		5,684			3,576			2,259
		Income tax expense	$	49,754		$	42,364		$	34,973
	Income tax expense from continuing operations for the years ended December 31, 2013, 2012 and 2011 differed from the amount computed by applying the U.S. federal income tax rate of 35% to earnings before income taxes as a result of the following (in thousands):
			2013			2012			2011
	Statutory federal income tax		$	107,984		$	92,325		$	78,143
	Less federal income tax assumed directly by noncontrolling interests			-65,142			-55,715			-48,394
	State income taxes, net of federal income tax benefit			5,539			5,309			3,642
	Increase in valuation allowances			924			419			1,622
	Interest related to unrecognized tax benefits			-155			-109			-83
	Other			604			135			43
		Income tax expense	$	49,754		$	42,364		$	34,973
	The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense. Decreases in interest obligations of $189,000, $132,000 and $109,000 were recognized in the consolidated statement of earnings for the years ended December 31, 2013, 2012 and 2011, respectively, resulting in a total recognition of interest obligations of approximately $943,000 and $1,132,000 in the consolidated balance sheet at December 31, 2013 and 2012, respectively. No amounts for penalties have been recorded.
	The Company primarily has unrecognized tax benefits that represent an amortization deduction which is temporary in nature. A reconciliation of the beginning and ending amount of the liability associated with unrecognized tax benefits for the years ended December 31, 2013, 2012 and 2011 is as follows (in thousands):
			2013			2012			2011
	Balance at beginning of year		$	9,235		$	7,252		$	7,144
	Additions for tax positions of current year			46			119			342
	Increases (decreases) for tax positions taken during a prior period			-			1,985			-190
	Lapse of statute of limitations			-2,951			-121			-44
		Balance at end of year	$	6,330		$	9,235		$	7,252
	The Company believes that the total amount of increases in unrecognized tax benefits within the next 12 months will not be significant. The total amount of unrecognized tax benefits that would affect the Company's effective tax rate if recognized is approximately $150,000.
	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities at December 31, 2013 and 2012 were as follows (in thousands):
				2013			2012
	Deferred tax assets:
		Allowance for uncollectible accounts		$	897		$	884
		Accrued assets and other			5,292			5,212
		Valuation allowances			-2,021			-2,084
			Total current deferred tax assets		4,168			4,012
		Share-based compensation			7,635			9,500
		Interest on unrecognized tax benefits			230			363
		Accrued liabilities and other			3,629			3,077
		Operating and capital loss carryforwards			9,185			9,169
		Valuation allowances			-7,665			-7,265
			Total non-current deferred tax assets		13,014			14,844
			Total deferred tax assets		17,182			18,856
	Deferred tax liabilities:
		Prepaid expenses			1,071			925
		Property and equipment, principally due to differences in depreciation			4,137			3,997
		Goodwill, principally due to differences in amortization			184,897			148,494
			Total deferred tax liabilities		190,105			153,416
			Net deferred tax liabilities	$	172,923		$	134,560
	The net deferred tax liabilities at December 31, 2013 and 2012 were recorded as follows (in thousands):
			2013			2012
	Current deferred income tax assets		$	3,097		$	3,088
	Non-current deferred income tax liabilities			176,020			137,648
		Net deferred tax liabilities	$	172,923		$	134,560
	The Company has provided valuation allowances on its gross deferred tax assets to the extent that management does not believe that it is more likely than not that such asset will be realized. Capital loss carryforwards will begin to expire in 2014, and state net operating losses will begin to expire in 2015.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Related Party Transactions Disclosure	'
	12. Related Party Transactions
	Certain surgery centers lease space from entities affiliated with their physician partners at negotiated rates that management believes were equal to fair market value at the inception of the leases based on relevant market data. Certain surgery centers reimburse their physician partners for salaries and benefits and billing fees related to time spent by employees of their practices on activities of the centers at current market rates. In addition, certain centers compensate at market rates their physician partners for physician advisory services provided to the surgery centers, including medical director and performance improvement services.
	Related party payments for the years ended December 31, 2013, 2012 and 2011 were as follows (in thousands):
		2013		2012		2011
	Operating leases	$	29,240	$	29,079	$	29,137
	Salaries and benefits		72,892		65,908		64,830
	Billing fees		11,591		11,126		11,240
	Medical advisory services		2,993		2,671		2,575
	The Company also reimburses their physician partners for operating expenses paid by the physician partners to third party providers on the behalf of the surgery center. The Company believes that the foregoing transactions are reasonably expected to benefit the Company and that the amount of reimbursed expenses included in other operating expenses in the accompanying consolidated statements of earnings for each of the years ended December 31, 2013, 2012 and 2011 were not significant.
	It is the Company's policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company's Board of Directors.

Employee_Benefit_Programs

Employee Benefit Programs	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	13. Employee Benefit Programs
	The Company maintains the AmSurg 401(k) Plan and Trust. This plan is a defined contribution plan covering substantially all employees of the Company and provides for voluntary contributions by these employees, subject to certain limits. Company contributions are based on specified percentages of employee compensation. The Company funds contributions as accrued. The Company's contributions for the years ended December 31, 2013, 2012 and 2011 were approximately $1,095,000, $1,031,000 and $594,000, respectively, and vest immediately or incrementally over five years, depending on the tenures of the respective employees for which the contributions were made.
	The Company maintains the Supplemental Executive and Director Retirement Savings Plan. This plan is a defined contribution plan covering all officers of the Company and provides for voluntary contributions of up to 50% of employee annual compensation. Company contributions are at the discretion of the Compensation Committee of the Board of Directors and vest incrementally over five years. The employee and employer contributions are placed in a Rabbi Trust and recorded in the accompanying consolidated balance sheets in prepaid and other current assets. Employer contributions to this plan for the years ended December 31, 2013, 2012 and 2011 were approximately $2,338,000, $1,693,000 and $915,000, respectively. On December 30, 2011, this plan was amended to allow non-employee directors to voluntarily contribute up to 100% of annual director cash compensation to the plan.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies	'
Commitments And Contingencies	'
	14. Commitments and Contingencies
	The Company and its subsidiaries are insured with respect to medical malpractice risk on a claims-made basis. The Company also maintains insurance for general liability, director and officer liability and property. Certain policies are subject to deductibles. In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. Management is not aware of any claims against it or its subsidiaries which would have a material financial impact on the Company.
	Certain of the Company's wholly owned subsidiaries, as general partners in the limited partnerships, are responsible for all debts incurred but unpaid by the limited partnership. As manager of the operations of the limited partnerships, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.
	In the event of a change in current law that would prohibit the physicians' current form of ownership in the partnerships, the Company would be obligated to purchase the physicians' interests in a majority of the Company's partnerships. The purchase price to be paid in such event would be determined by a predefined formula, as specified in the partnership agreements. The Company believes the likelihood of a change in current law, which would trigger such purchases, was remote as of December 31, 2013.
	On December 27, 2012, the Company entered into a lease agreement with an initial term of 15 years plus renewal options, pursuant to which the Company has agreed to lease an approximately 110,000 square foot building to be constructed in Nashville, Tennessee. The Company intends that the building will serve as its corporate headquarters beginning in 2015. Prior to taking possession, the Company may terminate the agreement if the landlord fails to satisfy certain construction milestones. The Company's annual rental obligation at the inception of the lease, which will occur upon completion of construction currently estimated to occur in late 2014, is approximately $2,300,000 and increases by 1.9% annually thereafter during the initial term. In addition to base rent, the Company will pay additional rent consisting of, among other things, operating expenses, real estate taxes and insurance costs. The landlord will provide the Company with an allowance of approximately $4,400,000 for certain interior tenant improvements.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Information	'
Supplemental Cash Flow Information	'
	15. Supplemental Cash Flow Information
	Supplemental cash flow information for the years ended December 31 2013, 2012 and 2011 is as follows (in thousands):
			2013		2012		2011
	Cash paid during the period for:
		Interest	$	28,378	$	14,786	$	13,815
		Income taxes, net of refunds		7,756		19,615		10,232
	Non-cash investing and financing activities:
		Increase in accounts payable associated with acquisition of property and equipment		884		248		659
		Capital lease obligations		738		1,096		466

Guarantor

Guarantor	12 Months Ended
	Dec. 31, 2013
Condensed Consolidating Financial Information	'
Condensed Consolidating Financial Information	'
	16. Financial Information for the Company and Its Subsidiaries
	The Senior Unsecured Notes, issued in 2012, are senior unsecured obligations of the Company and are guaranteed by the Company and certain of its existing and subsequently acquired or organized wholly owned domestic subsidiaries. The Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 "Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered." The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.
	Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)
									Guarantor			Non-Guarantor			Consolidating			Total
						Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Assets
	Current assets:
		Cash and cash equivalents				$	6,710		$	-		$	44,130		$	-		$	50,840
		Accounts receivable, net					-			-			105,072			-			105,072
		Supplies inventory					33			-			18,381			-			18,414
		Deferred income taxes					3,097			-			-			-			3,097
		Prepaid and other current assets					23,993			-			13,971			-4,362			33,602
			Total current assets				33,833			-			181,554			-4,362			211,025
	Property and equipment, net						9,829			-			160,066			-			169,895
	Investments in unconsolidated affiliates and long-term notes receivable						1,484,974			1,453,596			-			-2,922,178			16,392
	Goodwill and other intangible assets, net						20,684			-			978			1,758,970			1,780,632
				Total assets		$	1,549,320		$	1,453,596		$	342,598		$	-1,167,570		$	2,177,944
	Liabilities and Equity
	Current liabilities:
		Current portion of long-term debt				$	10,714		$	-		$	10,130		$	-		$	20,844
		Accounts payable					1,972			-			29,487			-3,958			27,501
		Other accrued liabilities					27,419			-			14,510			-404			41,525
			Total current liabilities				40,105			-			54,127			-4,362			89,870
	Long-term debt						561,429			-			53,246			-31,377			583,298
	Deferred income taxes						176,020			-			-			-			176,020
	Other long-term liabilities						7,569			-			17,934			-			25,503
	Noncontrolling interests – redeemable						-			-			63,704			113,993			177,697
	Equity:
			Total AmSurg Corp. equity				764,197			1,453,596			114,671			-1,568,267			764,197
			Noncontrolling interests – non-redeemable				-			-			38,916			322,443			361,359
			Total equity				764,197			1,453,596			153,587			-1,245,824			1,125,556
				Total liabilities and equity		$	1,549,320		$	1,453,596		$	342,598		$	-1,167,570		$	2,177,944
	Condensed Consolidating Balance Sheet - December 31, 2012 (In thousands)
									Guarantor			Non-Guarantor			Consolidating			Total
						Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Assets
	Current assets:
		Cash and cash equivalents				$	7,259		$	-		$	39,139		$	-		$	46,398
		Accounts receivable, net					-			-			96,752			-			96,752
		Supplies inventory					-			-			18,406			-			18,406
		Deferred income taxes					3,088			-			-			-			3,088
		Prepaid and other current assets					19,342			-			13,160			-4,965			27,537
			Total current assets				29,689			-			167,457			-4,965			192,181
	Property and equipment, net						9,199			-			157,413			-			166,612
	Investments in unconsolidated affiliates and long-term notes receivable						1,413,061			1,381,596			-			-2,783,383			11,274
	Goodwill and other intangible assets, net						21,311			-			1,206			1,652,002			1,674,519
				Total assets		$	1,473,260		$	1,381,596		$	326,076		$	-1,136,346		$	2,044,586
	Liabilities and Equity
	Current liabilities:
		Current portion of long-term debt				$	5,357		$	-		$	12,050		$	-		$	17,407
		Accounts payable					1,379			-			26,035			-3,905			23,509
		Other accrued liabilities					29,380			-			15,177			-1,060			43,497
			Total current liabilities				36,116			-			53,262			-4,965			84,413
	Long-term debt						599,423			-			52,747			-31,465			620,705
	Deferred income taxes						137,648			-			-			-			137,648
	Other long-term liabilities						10,585			-			15,387			-			25,972
	Noncontrolling interests – redeemable						-			-			61,939			113,443			175,382
	Equity:
			Total AmSurg Corp. equity				689,488			1,381,596			108,412			-1,490,008			689,488
			Noncontrolling interests – non-redeemable				-			-			34,329			276,649			310,978
			Total equity				689,488			1,381,596			142,741			-1,213,359			1,000,466
				Total liabilities and equity		$	1,473,260		$	1,381,596		$	326,076		$	-1,136,346		$	2,044,586
	Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2013 (In thousands)
								Guarantor			Non-Guarantor			Consolidating			Total
					Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Revenues					$	24,167		$	-		$	1,072,694		$	-17,518		$	1,079,343
Operating expenses:
	Salaries and benefits					61,038			-			272,619			-467			333,190
	Supply cost					-			-			157,771			-			157,771
	Other operating expenses					22,660			-			217,068			-17,051			222,677
	Depreciation and amortization					3,186			-			29,842			-			33,028
		Total operating expenses				86,884			-			677,300			-17,518			746,666
Gain on deconsolidation						2,237			2,237			-			-2,237			2,237
Equity in earnings of unconsolidated affiliates						204,962			204,962			-			-406,773			3,151
		Operating income				144,482			207,199			395,394			-409,010			338,065
Interest expense						27,282			-			2,256			-			29,538
	Earnings from continuing operations before income taxes					117,200			207,199			393,138			-409,010			308,527
Income tax expense						48,239			-			1,515			-			49,754
	Net earnings from continuing operations					68,961			207,199			391,623			-409,010			258,773
	Net earnings (loss) from discontinued operations					3,742			-			-971			-			2,771
		Net earnings				72,703			207,199			390,652			-409,010			261,544
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-			-			186,120			-			186,120
	Net earnings from discontinued operations					-			-			2,721			-			2,721
		Total net earnings attributable to noncontrolling interests				-			-			188,841			-			188,841
			Net earnings attributable to AmSurg Corp. common shareholders		$	72,703		$	207,199		$	201,811		$	-409,010		$	72,703
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	68,961		$	207,199		$	205,503		$	-409,010		$	72,653
	Discontinued operations, net of income tax					3,742			-			-3,692			-			50
			Net earnings attributable to AmSurg Corp. common shareholders		$	72,703		$	207,199		$	201,811		$	-409,010		$	72,703
Net earnings and comprehensive income, net of income tax					$	72,703		$	207,199		$	390,652		$	-409,010		$	261,544
	Less comprehensive income attributable to noncontrolling interests					-			-			188,841			-			188,841
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	72,703		$	207,199		$	201,811		$	-409,010		$	72,703
Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2012 (In thousands)
								Guarantor			Non-Guarantor			Consolidating			Total
					Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Revenues					$	19,907		$	-		$	918,176		$	-14,901		$	923,182
Operating expenses:
	Salaries and benefits					54,895			-			235,618			-450			290,063
	Supply cost					-			-			131,055			-			131,055
	Other operating expenses					20,499			-			186,977			-14,451			193,025
	Depreciation and amortization					2,860			-			26,990			-			29,850
		Total operating expenses				78,254			-			580,640			-14,901			643,993
Equity in earnings of unconsolidated affiliates						178,137			178,137			-			-354,710			1,564
		Operating income				119,790			178,137			337,536			-354,710			280,753
Interest expense						14,803			-			2,164			-			16,967
	Earnings from continuing operations before income taxes					104,987			178,137			335,372			-354,710			263,786
Income tax expense						40,810			-			1,554			-			42,364
	Net earnings from continuing operations					64,177			178,137			333,818			-354,710			221,422
	Net (loss) earnings from discontinued operations					-1,614			-			3,835			-			2,221
		Net earnings				62,563			178,137			337,653			-354,710			223,643
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-			-			159,187			-			159,187
	Net earnings from discontinued operations					-			-			1,893			-			1,893
		Total net earnings attributable to noncontrolling interests				-			-			161,080			-			161,080
			Net earnings attributable to AmSurg Corp. common shareholders		$	62,563		$	178,137		$	176,573		$	-354,710		$	62,563
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	64,177		$	178,137		$	174,631		$	-354,710		$	62,235
	Discontinued operations, net of income tax					-1,614			-			1,942			-			328
			Net earnings attributable to AmSurg Corp. common shareholders		$	62,563		$	178,137		$	176,573		$	-354,710		$	62,563
Net earnings and comprehensive income, net of income tax					$	62,563		$	178,137		$	337,653		$	-354,710		$	223,643
	Less comprehensive income attributable to noncontrolling interests					-			-			161,080			-			161,080
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	62,563		$	178,137		$	176,573		$	-354,710		$	62,563
Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2011 (In thousands)
								Guarantor			Non-Guarantor			Consolidating			Total
					Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Revenues					$	11,253		$	-		$	768,823		$	-8,001		$	772,075
Operating expenses:
	Salaries and benefits					42,739			-			196,358			-359			238,738
	Supply cost					-			-			101,364			-			101,364
	Other operating expenses					19,468			-			156,521			-7,642			168,347
	Depreciation and amortization					2,487			-			23,158			-			25,645
		Total operating expenses				64,694			-			477,401			-8,001			534,094
Equity in earnings of unconsolidated affiliates						152,409			152,409			-			-304,205			613
		Operating income				98,968			152,409			291,422			-304,205			238,594
Interest expense						13,195			-			2,132			-			15,327
	Earnings from continuing operations before income taxes					85,773			152,409			289,290			-304,205			223,267
Income tax expense						33,806			-			1,167			-			34,973
	Net earnings from continuing operations					51,967			152,409			288,123			-304,205			188,294
	Net (loss) earnings from discontinued operations					-1,970			-			3,790			-			1,820
		Net earnings				49,997			152,409			291,913			-304,205			190,114
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-			-			138,269			-			138,269
	Net earnings from discontinued operations					-			-			1,848			-			1,848
		Total net earnings attributable to noncontrolling interests				-			-			140,117			-			140,117
			Net earnings attributable to AmSurg Corp. common shareholders		$	49,997		$	152,409		$	151,796		$	-304,205		$	49,997
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	51,967		$	152,409		$	149,854		$	-304,205		$	50,025
	Discontinued operations, net of income tax					-1,970			-			1,942			-			-28
			Net earnings attributable to AmSurg Corp. common shareholders		$	49,997		$	152,409		$	151,796		$	-304,205		$	49,997
Net earnings					$	49,997		$	152,409		$	291,913		$	-304,205		$	190,114
Other comprehensive income, net of income tax:
	Unrealized gain on interest rate swap, net of income tax					515			-			-			-			515
		Comprehensive income, net of income tax				50,512			152,409			291,913			-304,205			190,629
	Less comprehensive income attributable to noncontrolling interests					-			-			140,117			-			140,117
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	50,512		$	152,409		$	151,796		$	-304,205		$	50,512
Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
				Parent			Guarantor			Non-Guarantor			Consolidating			Total
				Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Cash flows from operating activities:
		Net cash flows provided by operating activities		$	45,127		$	208,773		$	426,572		$	-347,648		$	332,824
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions				-			-74,288			-			694			-73,594
	Acquisition of property and equipment				-3,693			-			-25,163			-			-28,856
	Proceeds from sale of interests in surgery centers				-			3,553			-			-			3,553
	Other				-			159			-			-			159
		Net cash flows used in investing activities			-3,693			-70,576			-25,163			694			-98,738
Cash flows from financing activities:
	Proceeds from long-term borrowings				152,700			-			9,504			-			162,204
	Repayment on long-term borrowings				-188,081			-			-14,002			-			-202,083
	Distributions to owners, including noncontrolling interests				-			-138,875			-392,922			347,648			-184,149
	Changes in intercompany balances with affiliates, net				88			-			-88			-			-
	Other financing activities, net				-6,690			678			1,090			-694			-5,616
		Net cash flows used in financing activities			-41,983			-138,197			-396,418			346,954			-229,644
Net increase (decrease) in cash and cash equivalents					-549			-			4,991			-			4,442
Cash and cash equivalents, beginning of year					7,259			-			39,139			-			46,398
Cash and cash equivalents, end of year				$	6,710		$	-		$	44,130		$	-		$	50,840
Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2012 (In thousands)
				Parent			Guarantor			Non-Guarantor			Consolidating			Total
				Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities		$	-83,605		$	182,851		$	379,257		$	-182,851		$	295,652
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions				-90,029			-280,189			-			92,830			-277,388
	Acquisition of property and equipment				-3,681			-			-25,183			-			-28,864
	Proceeds from sale of interests in surgery centers				-			7,309			-			-			7,309
		Net cash flows used in investing activities			-93,710			-272,880			-25,183			92,830			-298,943
Cash flows from financing activities:
	Proceeds from long-term borrowings				560,000			-			5,566			-			565,566
	Repayment on long-term borrowings				-381,220			-			-12,944			-			-394,164
	Distributions to owners, including noncontrolling interests				-			-			-345,792			182,851			-162,941
	Capital contributions				-			90,029			-			-90,029			-
	Changes in intercompany balances with affiliates, net				-2,666			-			2,666			-			-
	Other financing activities, net				-70			-			3,381			-2,801			510
		Net cash flows provided by (used in) financing activities			176,044			90,029			-347,123			90,021			8,971
Net increase (decrease) in cash and cash equivalents					-1,271			-			6,951			-			5,680
Cash and cash equivalents, beginning of year					8,530			-			32,188			-			40,718
Cash and cash equivalents, end of year				$	7,259		$	-		$	39,139		$	-		$	46,398
Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2011 (In thousands)
				Parent			Guarantor			Non-Guarantor			Consolidating			Total
				Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Cash flows from operating activities:
		Net cash flows provided by (used in) operating activities		$	-67,911		$	151,558		$	311,334		$	-151,558		$	243,423
Cash flows from investing activities:
	Acquisition of interests in surgery centers and related transactions				-84,597			-243,429			-			88,803			-239,223
	Acquisition of property and equipment				-2,858			-			-19,312			-			-22,170
	Proceeds from sale of interests in surgery centers				-			7,274			-248			-			7,026
		Net cash flows used in investing activities			-87,455			-236,155			-19,560			88,803			-254,367
Cash flows from financing activities:
	Proceeds from long-term borrowings				281,100			-			7,769			-			288,869
	Repayment on long-term borrowings				-118,100			-			-11,007			-			-129,107
	Distributions to owners, including noncontrolling interests				-			-			-290,282			151,558			-138,724
	Capital contributions				-			84,597			-			-84,597			-
	Changes in intercompany balances with affiliates, net				-178			-			178			-			-
	Other financing activities, net				-3,609			-			4,292			-4,206			-3,523
		Net cash flows provided by (used in) financing activities			159,213			84,597			-289,050			62,755			17,515
Net increase in cash and cash equivalents					3,847			-			2,724			-			6,571
Cash and cash equivalents, beginning of year					4,683			-			29,464			-			34,147
Cash and cash equivalents, end of year				$	8,530		$	-		$	32,188		$	-		$	40,718

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events	'
Subsequent Events	'
	17. Subsequent Events
	The Company assessed events occurring subsequent to December 31, 2013 for potential recognition and disclosure in the consolidated financial statements. In January 2014, the Company, through a wholly owned subsidiary, acquired a majority interest in a surgery center for a purchase price of approximately $5,100,000. Other than as previously described, no events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

Quarterly_Financial_Data_Unaud

Quarterly Financial Data Unaudited	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data Abstract	'
Quarterly Financial Information Text Block	'
	Quarterly Statement of Earnings Data (Unaudited)
	The following table presents certain quarterly statement of earnings data for the years ended December 31, 2013 and 2012. The quarterly statement of earnings data set forth below was derived from the Company's unaudited financial statements and includes all adjustments, consisting of normal recurring adjustments, which the Company considers necessary for a fair presentation thereof. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.
			2013								2012
			Q1		Q2		Q3		Q4		Q1		Q2		Q3		Q4
			(In thousands, except per share data)
	Revenues		$	259,043	$	268,099	$	267,631	$	284,570	$	227,567	$	228,955	$	223,885	$	242,775
	Earnings from continuing operations
		before income taxes		74,496		78,398		73,989		81,644		66,110		66,611		63,211		67,854
	Net earnings from continuing operations			62,203		65,640		62,562		68,368		55,349		55,541		53,148		57,384
	Net earnings (loss) from
		discontinued operations (1)		70		196		-295		2,800		-410		4		617		2,010
	Net earnings			62,273		65,836		62,267		71,168		54,939		55,545		53,765		59,394
	Net earnings (loss) attributable to
		AmSurg Corp. common shareholders:
		Continuing		17,785		18,489		17,056		19,323		15,488		15,939		15,196		15,612
		Discontinued		26		74		-285		235		-712		-403		241		1,202
		Net earnings	$	17,811	$	18,563	$	16,771	$	19,558	$	14,776	$	15,536	$	15,437	$	16,814
	Diluted net earnings from
		continuing operations per common share	$	0.56	$	0.58	$	0.53	$	0.6	$	0.49	$	0.5	$	0.48	$	0.49
	Diluted net earnings per common share		$	0.56	$	0.58	$	0.52	$	0.61	$	0.47	$	0.49	$	0.49	$	0.53
	(1) Certain previously reported amounts have been reclassified for current year presentation for discontinued operations.

Schedule_II_Valuation_and_Qual

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation And Qualifying Accounts Abstract	'
Schedule Of Valuation And Qualifying Accounts Disclosure Text Block	'
	AmSurg Corp.
	Schedule II – Valuation and Qualifying Accounts
	For the Years Ended December 31, 2013, 2012 and 2011
	(In thousands)
					Additions				Deductions
			Balance at		Charged to		Charged to		Charge-off		Balance
			Beginning		Cost and		Other		Against		at End of
			of Period		Expenses		Accounts (1)		Allowances		Period
	Allowance for uncollectible accounts included under
		the balance sheet caption “Accounts receivable”:
	Year ended December 31, 2013		$	22,379	$	21,983	$	6,410	$	-22,910	$	27,862
	Year ended December 31, 2012		$	18,844	$	20,340	$	4,561	$	-21,366	$	22,379
	Year ended December 31, 2011		$	13,070	$	18,501	$	3,967	$	-16,694	$	18,844
	-1
	Valuation of allowance for uncollectible accounts as of the acquisition date of physician practice-based surgery centers, net of dispositions. See “Item 8. Financial Statements and Supplementary Data – Notes to the Consolidated Financial Statements – Note 2.”

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
Principles of Consolidation	'
	a.       Principles of Consolidation
	AmSurg Corp. (the “Company”), through its wholly owned subsidiaries, owns interests, primarily 51%, in limited partnerships and limited liability companies (“LLCs”) which own and operate ambulatory surgery centers (“centers”). The Company does not have an ownership interest in a limited partnership or LLC greater than 51% which it does not consolidate. The Company has ownership interests of less than 51% in six limited partnerships and LLCs, three of which it consolidates as the Company has substantive participation rights and three of which it does not consolidate as the Company's rights are limited to protective rights only. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and the consolidated limited partnerships and LLCs. Consolidation of such limited partnerships and LLCs is necessary as the Company's wholly owned subsidiaries have primarily 51% or more of the financial interest, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the limited partnerships and LLCs, and have control of the entities. The responsibilities of the Company's noncontrolling partners (limited partners and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests. Intercompany profits, transactions and balances have been eliminated. All limited partnerships and LLCs and noncontrolling partners are referred to herein as (“partnerships”) and (“partners”), respectively.
	Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company's equity. However, in instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required. Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of income; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary is measured at fair value. Certain transactions with noncontrolling interests are also classified within financing activities in the consolidated statements of cash flows.
	As further described in note 14, upon the occurrence of various fundamental regulatory changes, the Company would be obligated, under the terms of certain partnership and operating agreements, to purchase the noncontrolling interests related to a substantial majority of the Company's partnerships. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of December 31, 2013, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company's equity and are classified as noncontrolling interests – redeemable on the Company's consolidated balance sheets.
	Center profits and losses of consolidated entities are allocated to the Company's partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests. The partners of the Company's center partnerships typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each partner shares in the pre-tax earnings of the center in which it is a partner. Accordingly, the earnings attributable to noncontrolling interests in each of the Company's consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings. However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense. In addition, distributions from the partnerships are made to both the Company's wholly owned subsidiaries and the partners on a pre-tax basis.
	Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. These investments are included as investments in unconsolidated affiliates and long-term notes receivable in the accompanying consolidated balance sheets. The Company's share of the profits and losses from these investments are reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings and comprehensive income. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.
	Each of the Company's centers have similar economic characteristics and are aggregated into a single component. The Company operates this component as one reportable business segment, the ownership and operation of ambulatory surgery centers.
Cash and Cash Equivalents	'
	b.       Cash and Cash Equivalents
	Cash and cash equivalents are comprised principally of demand deposits at banks and other highly liquid short-term investments with maturities of less than three months when purchased.
Accounts Receivable	'
	c.       Accounts Receivable
	The determination of contractual and bad debt allowances constitutes a significant estimate. Some of the factors considered by management in determining the amount of such allowances are the historical trends of the centers' cash collections and contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors and procedure statistics. Accordingly, net accounts receivable at December 31, 2013 and 2012 reflect allowances for contractual adjustments of $289,937,000 and $216,363,000, respectively, and allowance for bad debt expense of $27,862,000 and $22,379,000, respectively.
Supplies Inventory	'
	d.       Supplies Inventory
	Supplies inventory consists of medical and drug supplies and is recorded at cost on a first-in, first-out basis.
Prepaids and Other Current Assets	'
	e.       Prepaid and Other Current Assets
	At December 31, 2013, prepaid and other current assets were comprised of short-term investments of $13,313,000, other prepaid expenses of $7,099,000, prepaid insurance expense of $5,631,000, other current receivables of $6,126,000 and other current assets of $1,433,000. At December 31, 2012, prepaid and other current assets were comprised of short-term investments of $8,804,000, other prepaid expenses of $6,462,000, prepaid insurance expense of $4,963,000, other current receivables of $5,926,000 and other current assets of $1,382,000.
Property and Equipment, net	'
	f.       Property and Equipment, net
	Property and equipment are stated at cost. Equipment held under capital leases is stated at the present value of minimum lease payments at the inception of the related leases. Depreciation for buildings and improvements is recognized under the straight-line method over 20 to 40 years or, for leasehold improvements, over the remaining term of the lease plus renewal options for which failure to renew the lease imposes a penalty on the Company in such an amount that a renewal appears, at the inception of the lease, to be reasonably assured. The primary penalty to which the Company is subject is the economic detriment associated with existing leasehold improvements which might be impaired if a decision is made not to continue the use of the leased property. Depreciation for movable equipment and software and software development costs is recognized over useful lives of three to ten years.
Goodwill	'
	g.       Goodwill
	The Company evaluates goodwill for impairment at least on an annual basis and more frequently if certain indicators are encountered. Goodwill is to be tested at the reporting unit level, defined as an operating segment or one level below an operating segment (referred to as a component), with the fair value of the reporting unit being compared to its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered to be impaired. The Company has determined that it has one operating, as well as one reportable, segment. For impairment testing purposes, the centers qualify as components of that operating segment. Because they have similar economic characteristics, the components are aggregated and deemed a single reporting unit. The Company completed its annual impairment test as of December 31, 2013, and determined that goodwill was not impaired.
Intangible Assets	'
	h.       Intangible Assets
	Intangible assets consist primarily of deferred financing costs of the Company and certain amortizable and non-amortizable non-compete and customer agreements. Deferred financing costs and amortizable non-compete agreements and customer agreements are amortized over the term of the related debt as interest expense and the contractual term or estimated life (five to ten years) of the agreements as amortization expense, respectively.
Other Long-Term Liabilities	'
	i.       Other Long-Term Liabilities
	At December 31, 2013, other long-term liabilities are comprised of deferred rent of $14,637,000, tax-effected unrecognized benefits of $6,888,000 (see note 1(k)), unfavorable lease liability of $3,034,000 and other long-term liabilities of $944,000. At December 31, 2012, other long-term liabilities are comprised of deferred rent of $12,134,000, tax-effected unrecognized benefits of $10,113,000 (see note 1(k)), unfavorable lease liability of $3,559,000 and other long-term liabilities of $166,000.
Revenue Recognition	'
	j.       Revenue Recognition
	Center revenues consist of billing for the use of the centers' facilities directly to the patient or third-party payor and, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by our centers. Such revenues are recognized when the related surgical procedures are performed. Revenues exclude any amounts billed for physicians' surgical services, which are billed separately by the physicians to the patient or third-party payor.
	Revenues from centers are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid. During the years ended December 31, 2013, 2012 and 2011, the Company derived approximately 25%, 27% and 29%, respectively, of its revenues from government healthcare programs, primarily Medicare, and managed Medicare programs. Concentration of credit risk with respect to other payors is limited due to the large number of such payors.
Operating Expenses	'
	k.       Operating Expenses
	Substantially all of the Company's operating expenses relate to the cost of revenues and the delivery of care at the Company's surgery centers. Such costs primarily include the surgery centers' clinical and administrative salaries and benefits, supply cost, rent and other variable expenses, such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense. Bad debt expense for continuing operations was approximately $21,947,000, $20,005,000 and $18,230,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
Income Taxes	'
	l.       Income Taxes
	The Company files a consolidated federal income tax return. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes. In addition, it is the Company's policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its statement of earnings. The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.
	The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various state jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2010.
Earnings Per Share	'
	m.       Earnings Per Share
	Basic earnings per share is computed by dividing net earnings attributable to AmSurg Corp. common shareholders by the combined weighted average number of common shares, while diluted earnings per share is computed by dividing net earnings attributable to AmSurg Corp. common shareholders by the weighted average number of such common shares and dilutive share equivalents.
Share-Based Compensation	'
	n.       Share-Based Compensation
	Transactions in which the Company receives employee and non-employee services in exchange for the Company's equity instruments or liabilities that are based on the fair value of the Company's equity securities or may be settled by the issuance of these securities are accounted using a fair value method. The Company applies the Black-Scholes method of valuation in determining share-based compensation expense.
	Benefits of tax deductions in excess of recognized compensation cost are reported as a financing cash flow, thus reducing the Company's net operating cash flows and increasing its financing cash flows by $7,247,000, $1,784,000 and $977,000 for the years ended December 31, 2013, 2012 and 2011, respectively.
	The Company examines its concentrations of holdings, its historical patterns of award exercises and forfeitures as well as forward-looking factors, in an effort to determine if there were any discernible employee populations. From this analysis, the Company has identified three employee populations, consisting of senior executives, officers and all other recipients. The expected volatility rate applied was estimated based on historical volatility. The expected term assumption applied is based on contractual terms, historical exercise and cancellation patterns and forward-looking factors where present for each population identified. The risk-free interest rate used is based on the U.S. Treasury yield curve in effect at the time of the grant. The pre-vesting forfeiture rate is based on historical rates and forward-looking factors for each population identified. The Company will adjust the estimated forfeiture rate to its actual experience. The Company intends to retain its earnings to finance growth and development of the business and does not expect to disclose or pay any cash dividends in the foreseeable future.
Use of Estimates	'
	o.       Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Reclassifications	'
	p.       Reclassifications
	Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 3.

Acquisitions_Policies

Acquisitions (Policies)	12 Months Ended
	Dec. 31, 2013
Acquisitions and Investments in Unconsolidated Affiliates	'
Business Combinations	'
	The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination. The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control. The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination. Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value.

Related_Party_Policies

Related Party (Policies)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Related Party	'
	It is the Company's policy that all transactions by the Company with officers, directors, five percent shareholders and their affiliates be entered into only if such transactions are on terms no less favorable to the Company than could be obtained from unaffiliated third parties, are reasonably expected to benefit the Company and are approved by the Nominating and Corporate Governance Committee of the Company's Board of Directors.

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Acquisitions and Investments in Unconsolidated Affiliates	'
Fair Value Of Total Consideration Transferred And Major Class Of Consideration	'
			2013			2012
	Accounts receivable		$	4,011		$	11,572
	Supplies inventory, prepaid and other current assets			2,014			4,750
	Property and equipment			6,894			23,546
	Goodwill			116,243			429,504
	Other intangible assets			-			800
	Accounts payable			-2,214			-3,199
	Other accrued liabilities			-532			-2,387
	Long-term debt			-3,028			-6,954
	Other long-term liabilities			-254			-
		Total fair value		123,134			457,632
		Less: Fair value attributable to noncontrolling interests		49,792			182,073
		Acquisition date fair value of total consideration transferred	$	73,342		$	275,559
Revenues And Net Earnings Associated With Acquisitions	'
			2013			2012
	Revenues		$	15,616		$	11,247
	Net earnings			4,596			3,441
	Less: Net earnings attributable to noncontrolling interests			2,603			1,977
		Net earnings attributable to AmSurg Corp. common shareholders	$	1,993		$	1,464
Consolidated Pro Forma Results Of Acquisition	'
					2013			2012
	Revenues				$	1,108,686		$	1,116,214
	Net earnings					269,903			261,251
	Amounts attributable to AmSurg Corp. common shareholders:
		Net earnings from continuing operations				75,411			76,893
		Net earnings				75,461			77,221
		Net earnings from continuing operations per common share:
			Basic		$	2.41		$	2.5
			Diluted		$	2.36		$	2.43
		Net earnings:
			Basic		$	2.41		$	2.51
			Diluted		$	2.36		$	2.44
		Weighted average number of shares and share equivalents:
			Basic			31,338			30,773
			Diluted			31,954			31,608

Dispositions_Tables

Dispositions (Tables)	12 Months Ended
	Dec. 31, 2013
Dispositions	'
Results Of Operations Of Centers Discontinued	'
		2013		2012		2011
	Cash proceeds from disposal	$	3,553	$	7,309	$	7,026
	Net earnings from discontinued operations		2,771		2,221		1,820
	Net gain (loss) from discontinued operations attributable to AmSurg Corp.		50		328		-28
Results Of Operations Of Combined Discontinued Surgery Centers	'
		2013		2012		2011
	Revenues	$	3,224	$	10,975	$	18,814
	Earnings before income taxes		227		2,724		4,318
	Net earnings		169		2,196		3,363

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment	'
Property, Plant and Equipment Schedule	'
			2013		2012
	Building and improvements		$	161,805	$	151,270
	Movable equipment and software			228,212		208,541
	Construction in progress			2,321		2,313
				392,338		362,124
	Less accumulated depreciation			-222,443		-195,512
		Property and equipment, net	$	169,895	$	166,612

Goodwill_And_Intangible_Assets1

Goodwill And Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill And Intangible Assets	'
Changes In Carrying Amount Of Goodwill	'
			2013		2012
	Balance, beginning of period		$	1,652,002	$	1,229,298
	Goodwill acquired, including post acquisition adjustments			112,951		429,504
	Goodwill disposed, including impact of deconsolidation transaction			-5,983		-6,800
		Balance, end of period	$	1,758,970	$	1,652,002
Schedule of Finite-Lived Intangible Assets	'
					2013						2012
					Gross						Gross
					Carrying		Accumulated				Carrying		Accumulated
					Amount		Amortization		Net		Amount		Amortization		Net
	Deferred financing cost				$	15,814	$	-4,953	$	10,861	$	14,523	$	-3,029	$	11,494
	Agreements, contracts and other intangible assets					3,448		-2,472		976		3,448		-2,250		1,198
				Total amortizable intangible assets	$	19,262	$	-7,425	$	11,837	$	17,971	$	-5,279	$	12,692

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Long-Term Debt	'
Components Of Long-Term Debt	'
				2013		2012
	Revolving credit agreement (average rate of 2.1%)			$	252,500	$	279,780
	Senior Unsecured Notes due 2020 (5.625%)				250,000		250,000
	Senior Secured Notes due 2020 (8.04%)				69,643		75,000
	Other debt at an average rate of 3.6%, due through 2025				21,149		21,350
	Capitalized lease arrangements at an average rate of 5.3%, due through 2026				10,850		11,982
					604,142		638,112
	Less current portion				20,844		17,407
		Long-term debt		$	583,298	$	620,705
Redemption Price Percentage	'
	Period		Redemption Price
	2015		104.22%
	2016		102.81%
	2017		101.41%
	2018 and thereafter		100.00%

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Measurements	'
Fair Value Of Assets And Liabilities Measured On A Recurring Basis	'
			2013		2012
	Assets:
		Supplemental executive retirement savings plan investments - Level 2	$	13,313	$	8,804
	Liabilities:
		Contingent purchase price payable - Level 3 (see note 2)	$	-	$	2,744

Leases_Tables

Leases (Tables)	12 Months Ended
	Dec. 31, 2013
Leases	'
Future Minimum Lease Payment Schedule	'
			Capitalized		Operating
	Year Ended December 31,		Equipment Leases		Leases
	2014		$	2,040	$	47,704
	2015			1,673		46,557
	2016			1,404		45,772
	2017			1,184		45,174
	2018			1,000		43,718
	Thereafter			7,003		354,087
		Total minimum rentals		14,304	$	583,012
	Less amounts representing interest at rates ranging from 2.9% to 11.8%			3,454
		Capital lease obligations	$	10,850

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Shareholders' Equity	'
Share-Based Activity	'
		2013			2012			2011
	Share-based compensation expense	$	8,321		$	6,692		$	6,178
	Fair value of shares vested		11,742			6,425			7,356
	Cash received from option exercises		33,349			18,214			6,872
	Tax benefit from option exercises		7,247			1,784			977
Schedule Of Changes In Non-Vested Restricted Shares	'
							Weighted
					Number		Average
					of		Grant
					Shares		Price
	Non-vested shares at January 1, 2011				664,909		$	22.16
		Shares granted			276,869			21.78
		Shares vested			-208,949			23.11
		Shares forfeited			-417			24.75
	Non-vested shares at December 31, 2011				732,412		$	21.91
		Shares granted			281,429			26.78
		Shares vested			-183,019			25.98
		Shares forfeited			-2,136			26.26
	Non-vested shares at December 31, 2012				828,686		$	22.5
		Shares granted			291,863			31.66
		Shares vested			-360,337			21.55
		Shares forfeited			-16,343			23.11
	Non-vested shares at December 31, 2013				743,869		$	26.54
Schedule Of Stock Option Activity	'
									Weighted
									Average
						Weighted			Remaining
				Number		Average			Contractual
				of		Exercise			Term
				Shares		Price			(in years)
	Outstanding at January 1, 2011			2,901,989		$	22.49		4.5
		Options exercised with total intrinsic value of $2,482,000		-374,350			18.36
		Options terminated		-17,585			25.42
	Outstanding at December 31, 2011			2,510,054		$	23.09		3.4
		Options exercised with total intrinsic value of $6,287,000		-841,599			21.64
		Options terminated		-5,625			21.85
	Outstanding at December 31, 2012			1,662,830		$	23.82		2.9
		Options exercised with total intrinsic value of $33,349,000		-1,392,366			23.95
	Outstanding at December 31, 2013 with aggregate intrinsic value of $6,156,000			270,464		$	23.16		2.5
	Vested or expected to vest at December 31, 2013 with total intrinsic value of $6,156,000			270,464		$	23.16		2.5
	Exercisable at December 31, 2013 with total intrinsic value of $6,156,000			270,464		$	23.16		2.5
Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share	'
										Per
					Earnings			Shares		Share
					(Numerator)			(Denominator)		Amount
	For the year ended December 31, 2013:
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (basic)		$	72,653		31,338		$	2.32
		Effect of dilutive securities options and non-vested shares				-		616
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (diluted)		$	72,653		31,954		$	2.27
		Net earnings attributable to AmSurg Corp. per common share (basic)			$	72,703		31,338		$	2.32
		Effect of dilutive securities options and non-vested shares				-		616
		Net earnings attributable to AmSurg Corp. per common share (diluted)			$	72,703		31,954		$	2.28
	For the year ended December 31, 2012:
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (basic)		$	62,235		30,773		$	2.02
		Effect of dilutive securities options and non-vested shares				-		835
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (diluted)		$	62,235		31,608		$	1.97
		Net earnings attributable to AmSurg Corp. per common share (basic)			$	62,563		30,773		$	2.03
		Effect of dilutive securities options and non-vested shares				-		835
		Net earnings attributable to AmSurg Corp. per common share (diluted)			$	62,563		31,608		$	1.98
	For the year ended December 31, 2011:
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (basic)		$	50,025		30,452		$	1.64
		Effect of dilutive securities options and non-vested shares				-		759
		Net earnings from continuing operations attributable to
			AmSurg Corp. per common share (diluted)		$	50,025		31,211		$	1.6
		Net earnings attributable to AmSurg Corp. per common share (basic)			$	49,997		30,452		$	1.64
		Effect of dilutive securities options and non-vested shares				-		759
		Net earnings attributable to AmSurg Corp. per common share (diluted)			$	49,997		31,211		$	1.6

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
Schedule Of Total Income Tax Expense	'
			2013			2012			2011
	Income from continuing operations		$	49,754		$	42,364		$	34,973
	Discontinued operations			-1,091			1,574			3,032
	Shareholders’ equity			-7,381			-1,581			-649
	Other comprehensive income			-			-			332
		Total	$	41,282		$	42,357		$	37,688
Schedule of Components of Income Tax Expense (Benefit)	'
			2013			2012			2011
	Current:
		Federal	$	8,437		$	15,326		$	11,671
		State		3,724			4,974			3,541
	Deferred:
		Federal		31,909			18,488			17,502
		State		5,684			3,576			2,259
		Income tax expense	$	49,754		$	42,364		$	34,973
Schedule of Effective Income Tax Rate Reconciliation	'
			2013			2012			2011
	Statutory federal income tax		$	107,984		$	92,325		$	78,143
	Less federal income tax assumed directly by noncontrolling interests			-65,142			-55,715			-48,394
	State income taxes, net of federal income tax benefit			5,539			5,309			3,642
	Increase in valuation allowances			924			419			1,622
	Interest related to unrecognized tax benefits			-155			-109			-83
	Other			604			135			43
		Income tax expense	$	49,754		$	42,364		$	34,973
Summary of Income Tax Contingencies	'
			2013			2012			2011
	Balance at beginning of year		$	9,235		$	7,252		$	7,144
	Additions for tax positions of current year			46			119			342
	Increases (decreases) for tax positions taken during a prior period			-			1,985			-190
	Lapse of statute of limitations			-2,951			-121			-44
		Balance at end of year	$	6,330		$	9,235		$	7,252
Schedule of Deferred Tax Assets and Liabilities	'
				2013			2012
	Deferred tax assets:
		Allowance for uncollectible accounts		$	897		$	884
		Accrued assets and other			5,292			5,212
		Valuation allowances			-2,021			-2,084
			Total current deferred tax assets		4,168			4,012
		Share-based compensation			7,635			9,500
		Interest on unrecognized tax benefits			230			363
		Accrued liabilities and other			3,629			3,077
		Operating and capital loss carryforwards			9,185			9,169
		Valuation allowances			-7,665			-7,265
			Total non-current deferred tax assets		13,014			14,844
			Total deferred tax assets		17,182			18,856
	Deferred tax liabilities:
		Prepaid expenses			1,071			925
		Property and equipment, principally due to differences in depreciation			4,137			3,997
		Goodwill, principally due to differences in amortization			184,897			148,494
			Total deferred tax liabilities		190,105			153,416
			Net deferred tax liabilities	$	172,923		$	134,560
Schedule Of Deferred Tax Assets And Liabilities, Net [Table Text Block]	'
			2013			2012
	Current deferred income tax assets		$	3,097		$	3,088
	Non-current deferred income tax liabilities			176,020			137,648
		Net deferred tax liabilities	$	172,923		$	134,560

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2013
Related Party Transactions	'
Schedule of Related Party Payments	'
		2013		2012		2011
	Operating leases	$	29,240	$	29,079	$	29,137
	Salaries and benefits		72,892		65,908		64,830
	Billing fees		11,591		11,126		11,240
	Medical advisory services		2,993		2,671		2,575

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2013
Supplemental Cash Flow Information	'
Summary Of Supplemental Cash Flow Information	'
			2013		2012		2011
	Cash paid during the period for:
		Interest	$	28,378	$	14,786	$	13,815
		Income taxes, net of refunds		7,756		19,615		10,232
	Non-cash investing and financing activities:
		Increase in accounts payable associated with acquisition of property and equipment		884		248		659
		Capital lease obligations		738		1,096		466

Guarantor_Tables

Guarantor (Tables)	12 Months Ended
	Dec. 31, 2013
Condensed Consolidating Financial Information	'
Condensed Consolidating Balance Sheet	'
	Condensed Consolidating Balance Sheet - December 31, 2013 (In thousands)
									Guarantor			Non-Guarantor			Consolidating			Total
						Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Assets
	Current assets:
		Cash and cash equivalents				$	6,710		$	-		$	44,130		$	-		$	50,840
		Accounts receivable, net					-			-			105,072			-			105,072
		Supplies inventory					33			-			18,381			-			18,414
		Deferred income taxes					3,097			-			-			-			3,097
		Prepaid and other current assets					23,993			-			13,971			-4,362			33,602
			Total current assets				33,833			-			181,554			-4,362			211,025
	Property and equipment, net						9,829			-			160,066			-			169,895
	Investments in unconsolidated affiliates and long-term notes receivable						1,484,974			1,453,596			-			-2,922,178			16,392
	Goodwill and other intangible assets, net						20,684			-			978			1,758,970			1,780,632
				Total assets		$	1,549,320		$	1,453,596		$	342,598		$	-1,167,570		$	2,177,944
	Liabilities and Equity
	Current liabilities:
		Current portion of long-term debt				$	10,714		$	-		$	10,130		$	-		$	20,844
		Accounts payable					1,972			-			29,487			-3,958			27,501
		Other accrued liabilities					27,419			-			14,510			-404			41,525
			Total current liabilities				40,105			-			54,127			-4,362			89,870
	Long-term debt						561,429			-			53,246			-31,377			583,298
	Deferred income taxes						176,020			-			-			-			176,020
	Other long-term liabilities						7,569			-			17,934			-			25,503
	Noncontrolling interests – redeemable						-			-			63,704			113,993			177,697
	Equity:
			Total AmSurg Corp. equity				764,197			1,453,596			114,671			-1,568,267			764,197
			Noncontrolling interests – non-redeemable				-			-			38,916			322,443			361,359
			Total equity				764,197			1,453,596			153,587			-1,245,824			1,125,556
				Total liabilities and equity		$	1,549,320		$	1,453,596		$	342,598		$	-1,167,570		$	2,177,944
	Condensed Consolidating Balance Sheet - December 31, 2012 (In thousands)
									Guarantor			Non-Guarantor			Consolidating			Total
						Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Assets
	Current assets:
		Cash and cash equivalents				$	7,259		$	-		$	39,139		$	-		$	46,398
		Accounts receivable, net					-			-			96,752			-			96,752
		Supplies inventory					-			-			18,406			-			18,406
		Deferred income taxes					3,088			-			-			-			3,088
		Prepaid and other current assets					19,342			-			13,160			-4,965			27,537
			Total current assets				29,689			-			167,457			-4,965			192,181
	Property and equipment, net						9,199			-			157,413			-			166,612
	Investments in unconsolidated affiliates and long-term notes receivable						1,413,061			1,381,596			-			-2,783,383			11,274
	Goodwill and other intangible assets, net						21,311			-			1,206			1,652,002			1,674,519
				Total assets		$	1,473,260		$	1,381,596		$	326,076		$	-1,136,346		$	2,044,586
	Liabilities and Equity
	Current liabilities:
		Current portion of long-term debt				$	5,357		$	-		$	12,050		$	-		$	17,407
		Accounts payable					1,379			-			26,035			-3,905			23,509
		Other accrued liabilities					29,380			-			15,177			-1,060			43,497
			Total current liabilities				36,116			-			53,262			-4,965			84,413
	Long-term debt						599,423			-			52,747			-31,465			620,705
	Deferred income taxes						137,648			-			-			-			137,648
	Other long-term liabilities						10,585			-			15,387			-			25,972
	Noncontrolling interests – redeemable						-			-			61,939			113,443			175,382
	Equity:
			Total AmSurg Corp. equity				689,488			1,381,596			108,412			-1,490,008			689,488
			Noncontrolling interests – non-redeemable				-			-			34,329			276,649			310,978
			Total equity				689,488			1,381,596			142,741			-1,213,359			1,000,466
				Total liabilities and equity		$	1,473,260		$	1,381,596		$	326,076		$	-1,136,346		$	2,044,586
Condensed Consolidating Statement of Earnings and Comprehensive Income	'
	Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2013 (In thousands)
									Guarantor			Non-Guarantor			Consolidating			Total
						Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Revenues					$	24,167		$	-		$	1,072,694		$	-17,518		$	1,079,343
	Operating expenses:
		Salaries and benefits					61,038			-			272,619			-467			333,190
		Supply cost					-			-			157,771			-			157,771
		Other operating expenses					22,660			-			217,068			-17,051			222,677
		Depreciation and amortization					3,186			-			29,842			-			33,028
			Total operating expenses				86,884			-			677,300			-17,518			746,666
	Gain on deconsolidation						2,237			2,237			-			-2,237			2,237
	Equity in earnings of unconsolidated affiliates						204,962			204,962			-			-406,773			3,151
			Operating income				144,482			207,199			395,394			-409,010			338,065
	Interest expense						27,282			-			2,256			-			29,538
		Earnings from continuing operations before income taxes					117,200			207,199			393,138			-409,010			308,527
	Income tax expense						48,239			-			1,515			-			49,754
		Net earnings from continuing operations					68,961			207,199			391,623			-409,010			258,773
		Net earnings (loss) from discontinued operations					3,742			-			-971			-			2,771
			Net earnings				72,703			207,199			390,652			-409,010			261,544
	Less net earnings attributable to noncontrolling interests:
		Net earnings from continuing operations					-			-			186,120			-			186,120
		Net earnings from discontinued operations					-			-			2,721			-			2,721
			Total net earnings attributable to noncontrolling interests				-			-			188,841			-			188,841
				Net earnings attributable to AmSurg Corp. common shareholders		$	72,703		$	207,199		$	201,811		$	-409,010		$	72,703
	Amounts attributable to AmSurg Corp. common shareholders:
		Earnings from continuing operations, net of income tax				$	68,961		$	207,199		$	205,503		$	-409,010		$	72,653
		Discontinued operations, net of income tax					3,742			-			-3,692			-			50
				Net earnings attributable to AmSurg Corp. common shareholders		$	72,703		$	207,199		$	201,811		$	-409,010		$	72,703
	Net earnings and comprehensive income, net of income tax					$	72,703		$	207,199		$	390,652		$	-409,010		$	261,544
		Less comprehensive income attributable to noncontrolling interests					-			-			188,841			-			188,841
			Comprehensive income attributable to AmSurg Corp.
					common shareholders	$	72,703		$	207,199		$	201,811		$	-409,010		$	72,703
	Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2012 (In thousands)
									Guarantor			Non-Guarantor			Consolidating			Total
						Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Revenues					$	19,907		$	-		$	918,176		$	-14,901		$	923,182
	Operating expenses:
		Salaries and benefits					54,895			-			235,618			-450			290,063
		Supply cost					-			-			131,055			-			131,055
		Other operating expenses					20,499			-			186,977			-14,451			193,025
		Depreciation and amortization					2,860			-			26,990			-			29,850
			Total operating expenses				78,254			-			580,640			-14,901			643,993
	Equity in earnings of unconsolidated affiliates						178,137			178,137			-			-354,710			1,564
			Operating income				119,790			178,137			337,536			-354,710			280,753
	Interest expense						14,803			-			2,164			-			16,967
		Earnings from continuing operations before income taxes					104,987			178,137			335,372			-354,710			263,786
	Income tax expense						40,810			-			1,554			-			42,364
		Net earnings from continuing operations					64,177			178,137			333,818			-354,710			221,422
		Net (loss) earnings from discontinued operations					-1,614			-			3,835			-			2,221
			Net earnings				62,563			178,137			337,653			-354,710			223,643
	Less net earnings attributable to noncontrolling interests:
		Net earnings from continuing operations					-			-			159,187			-			159,187
		Net earnings from discontinued operations					-			-			1,893			-			1,893
			Total net earnings attributable to noncontrolling interests				-			-			161,080			-			161,080
				Net earnings attributable to AmSurg Corp. common shareholders		$	62,563		$	178,137		$	176,573		$	-354,710		$	62,563
	Amounts attributable to AmSurg Corp. common shareholders:
		Earnings from continuing operations, net of income tax				$	64,177		$	178,137		$	174,631		$	-354,710		$	62,235
		Discontinued operations, net of income tax					-1,614			-			1,942			-			328
				Net earnings attributable to AmSurg Corp. common shareholders		$	62,563		$	178,137		$	176,573		$	-354,710		$	62,563
	Net earnings and comprehensive income, net of income tax					$	62,563		$	178,137		$	337,653		$	-354,710		$	223,643
		Less comprehensive income attributable to noncontrolling interests					-			-			161,080			-			161,080
			Comprehensive income attributable to AmSurg Corp.
					common shareholders	$	62,563		$	178,137		$	176,573		$	-354,710		$	62,563
Condensed Consolidating Statement of Earnings and Comprehensive Income - Year Ended December 31, 2011 (In thousands)
								Guarantor			Non-Guarantor			Consolidating			Total
					Parent Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
Revenues					$	11,253		$	-		$	768,823		$	-8,001		$	772,075
Operating expenses:
	Salaries and benefits					42,739			-			196,358			-359			238,738
	Supply cost					-			-			101,364			-			101,364
	Other operating expenses					19,468			-			156,521			-7,642			168,347
	Depreciation and amortization					2,487			-			23,158			-			25,645
		Total operating expenses				64,694			-			477,401			-8,001			534,094
Equity in earnings of unconsolidated affiliates						152,409			152,409			-			-304,205			613
		Operating income				98,968			152,409			291,422			-304,205			238,594
Interest expense						13,195			-			2,132			-			15,327
	Earnings from continuing operations before income taxes					85,773			152,409			289,290			-304,205			223,267
Income tax expense						33,806			-			1,167			-			34,973
	Net earnings from continuing operations					51,967			152,409			288,123			-304,205			188,294
	Net (loss) earnings from discontinued operations					-1,970			-			3,790			-			1,820
		Net earnings				49,997			152,409			291,913			-304,205			190,114
Less net earnings attributable to noncontrolling interests:
	Net earnings from continuing operations					-			-			138,269			-			138,269
	Net earnings from discontinued operations					-			-			1,848			-			1,848
		Total net earnings attributable to noncontrolling interests				-			-			140,117			-			140,117
			Net earnings attributable to AmSurg Corp. common shareholders		$	49,997		$	152,409		$	151,796		$	-304,205		$	49,997
Amounts attributable to AmSurg Corp. common shareholders:
	Earnings from continuing operations, net of income tax				$	51,967		$	152,409		$	149,854		$	-304,205		$	50,025
	Discontinued operations, net of income tax					-1,970			-			1,942			-			-28
			Net earnings attributable to AmSurg Corp. common shareholders		$	49,997		$	152,409		$	151,796		$	-304,205		$	49,997
Net earnings					$	49,997		$	152,409		$	291,913		$	-304,205		$	190,114
Other comprehensive income, net of income tax:
	Unrealized gain on interest rate swap, net of income tax					515			-			-			-			515
		Comprehensive income, net of income tax				50,512			152,409			291,913			-304,205			190,629
	Less comprehensive income attributable to noncontrolling interests					-			-			140,117			-			140,117
		Comprehensive income attributable to AmSurg Corp.
				common shareholders	$	50,512		$	152,409		$	151,796		$	-304,205		$	50,512
Condensed Consolidating Cash Flow Statement	'
	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2013 (In thousands)
					Parent			Guarantor			Non-Guarantor			Consolidating			Total
					Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Cash flows from operating activities:
			Net cash flows provided by operating activities		$	45,127		$	208,773		$	426,572		$	-347,648		$	332,824
	Cash flows from investing activities:
		Acquisition of interests in surgery centers and related transactions				-			-74,288			-			694			-73,594
		Acquisition of property and equipment				-3,693			-			-25,163			-			-28,856
		Proceeds from sale of interests in surgery centers				-			3,553			-			-			3,553
		Other				-			159			-			-			159
			Net cash flows used in investing activities			-3,693			-70,576			-25,163			694			-98,738
	Cash flows from financing activities:
		Proceeds from long-term borrowings				152,700			-			9,504			-			162,204
		Repayment on long-term borrowings				-188,081			-			-14,002			-			-202,083
		Distributions to owners, including noncontrolling interests				-			-138,875			-392,922			347,648			-184,149
		Changes in intercompany balances with affiliates, net				88			-			-88			-			-
		Other financing activities, net				-6,690			678			1,090			-694			-5,616
			Net cash flows used in financing activities			-41,983			-138,197			-396,418			346,954			-229,644
	Net increase (decrease) in cash and cash equivalents					-549			-			4,991			-			4,442
	Cash and cash equivalents, beginning of year					7,259			-			39,139			-			46,398
	Cash and cash equivalents, end of year				$	6,710		$	-		$	44,130		$	-		$	50,840
	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2012 (In thousands)
					Parent			Guarantor			Non-Guarantor			Consolidating			Total
					Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Cash flows from operating activities:
			Net cash flows provided by (used in) operating activities		$	-83,605		$	182,851		$	379,257		$	-182,851		$	295,652
	Cash flows from investing activities:
		Acquisition of interests in surgery centers and related transactions				-90,029			-280,189			-			92,830			-277,388
		Acquisition of property and equipment				-3,681			-			-25,183			-			-28,864
		Proceeds from sale of interests in surgery centers				-			7,309			-			-			7,309
			Net cash flows used in investing activities			-93,710			-272,880			-25,183			92,830			-298,943
	Cash flows from financing activities:
		Proceeds from long-term borrowings				560,000			-			5,566			-			565,566
		Repayment on long-term borrowings				-381,220			-			-12,944			-			-394,164
		Distributions to owners, including noncontrolling interests				-			-			-345,792			182,851			-162,941
		Capital contributions				-			90,029			-			-90,029			-
		Changes in intercompany balances with affiliates, net				-2,666			-			2,666			-			-
		Other financing activities, net				-70			-			3,381			-2,801			510
			Net cash flows provided by (used in) financing activities			176,044			90,029			-347,123			90,021			8,971
	Net increase (decrease) in cash and cash equivalents					-1,271			-			6,951			-			5,680
	Cash and cash equivalents, beginning of year					8,530			-			32,188			-			40,718
	Cash and cash equivalents, end of year				$	7,259		$	-		$	39,139		$	-		$	46,398
	Condensed Consolidating Statement of Cash Flows - Year Ended December 31, 2011 (In thousands)
					Parent			Guarantor			Non-Guarantor			Consolidating			Total
					Issuer			Subsidiaries			Subsidiaries			Adjustments			Consolidated
	Cash flows from operating activities:
			Net cash flows provided by (used in) operating activities		$	-67,911		$	151,558		$	311,334		$	-151,558		$	243,423
	Cash flows from investing activities:
		Acquisition of interests in surgery centers and related transactions				-84,597			-243,429			-			88,803			-239,223
		Acquisition of property and equipment				-2,858			-			-19,312			-			-22,170
		Proceeds from sale of interests in surgery centers				-			7,274			-248			-			7,026
			Net cash flows used in investing activities			-87,455			-236,155			-19,560			88,803			-254,367
	Cash flows from financing activities:
		Proceeds from long-term borrowings				281,100			-			7,769			-			288,869
		Repayment on long-term borrowings				-118,100			-			-11,007			-			-129,107
		Distributions to owners, including noncontrolling interests				-			-			-290,282			151,558			-138,724
		Capital contributions				-			84,597			-			-84,597			-
		Changes in intercompany balances with affiliates, net				-178			-			178			-			-
		Other financing activities, net				-3,609			-			4,292			-4,206			-3,523
			Net cash flows provided by (used in) financing activities			159,213			84,597			-289,050			62,755			17,515
	Net increase in cash and cash equivalents					3,847			-			2,724			-			6,571
	Cash and cash equivalents, beginning of year					4,683			-			29,464			-			34,147
	Cash and cash equivalents, end of year				$	8,530		$	-		$	32,188		$	-		$	40,718

Quarterly_Financial_Data_Unaud1

Quarterly Financial Data Unaudited (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Data Abstract	'
Schedule of Quarterly Financial Information [Table Text Block]	'
			2013								2012
			Q1		Q2		Q3		Q4		Q1		Q2		Q3		Q4
			(In thousands, except per share data)
	Revenues		$	259,043	$	268,099	$	267,631	$	284,570	$	227,567	$	228,955	$	223,885	$	242,775
	Earnings from continuing operations
		before income taxes		74,496		78,398		73,989		81,644		66,110		66,611		63,211		67,854
	Net earnings from continuing operations			62,203		65,640		62,562		68,368		55,349		55,541		53,148		57,384
	Net earnings (loss) from
		discontinued operations (1)		70		196		-295		2,800		-410		4		617		2,010
	Net earnings			62,273		65,836		62,267		71,168		54,939		55,545		53,765		59,394
	Net earnings (loss) attributable to
		AmSurg Corp. common shareholders:
		Continuing		17,785		18,489		17,056		19,323		15,488		15,939		15,196		15,612
		Discontinued		26		74		-285		235		-712		-403		241		1,202
		Net earnings	$	17,811	$	18,563	$	16,771	$	19,558	$	14,776	$	15,536	$	15,437	$	16,814
	Diluted net earnings from
		continuing operations per common share	$	0.56	$	0.58	$	0.53	$	0.6	$	0.49	$	0.5	$	0.48	$	0.49
	Diluted net earnings per common share		$	0.56	$	0.58	$	0.52	$	0.61	$	0.47	$	0.49	$	0.49	$	0.53

Schedule_II_Valuation_and_Qual1

Schedule II Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2013
Valuation And Qualifying Accounts Abstract	'
Schedule Of Valuation And Qualifying Accounts Disclosure	'
					Additions				Deductions
			Balance at		Charged to		Charged to		Charge-off		Balance
			Beginning		Cost and		Other		Against		at End of
			of Period		Expenses		Accounts (1)		Allowances		Period
	Allowance for uncollectible accounts included under
		the balance sheet caption “Accounts receivable”:
	Year ended December 31, 2013		$	22,379	$	21,983	$	6,410	$	-22,910	$	27,862
	Year ended December 31, 2012		$	18,844	$	20,340	$	4,561	$	-21,366	$	22,379
	Year ended December 31, 2011		$	13,070	$	18,501	$	3,967	$	-16,694	$	18,844

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Centers
Accounts Receivable, Net [Abstract]	'	'	'
Allowances for contractual adjustments	$289,937,000	$216,363,000	'
Allowances for accounts receivable	27,862,000	22,379,000	'
Income Taxes	'	'	'
Open Tax Year	'2010	'	'
Operating Expenses [Abstract]	'	'	'
Bad debt expense included in other operating expenses	21,947,000	20,005,000	18,230,000
Other Long Term Liabilities	'	'	'
Deferred Rent Credit, Noncurrent	14,637,000	12,134,000	'
Liability for Uncertain Tax Positions, Noncurrent	6,888,000	10,113,000	'
Off-market Lease, Unfavorable	3,034,000	3,559,000	'
Other long-term liabilities	944,000	166,000	'
Prepaid Expense and Other Current Assets	'	'	'
Short-term Investments	13,313,000	8,804,000	'
Other Prepaid Expense, Current	7,099,000	6,462,000	'
Prepaid Insurance	5,631,000	4,963,000	'
Accounts and Other Receivables, Net, Current	6,126,000	5,926,000	'
Other Assets, Current	1,433,000	1,382,000	'
Ownership Interests [Line Items]	'	'	'
Number Of Centers Owned Less Than 51 Percent	6	'	'
Ownership Interest In Unconsolidated Minority Owned Partnerships	20.00%	'	'
Revenue Recognition	'	'	'
Percentage of revenues from governmental healthcare programs	25.00%	27.00%	29.00%
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years 8 months 12 days	'	'
Share-based Compensation [Abstract]	'	'	'
Excess Tax Benefit from Share-based Compensation, Financing Activities	$7,247,000	$1,784,000	$977,000
Maximum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'10 years	'	'
Maximum [Member] | Building and Building Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'40 years	'	'
Maximum [Member] | Machinery and Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'10 years	'	'
Minimum [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years	'	'
Minimum [Member] | Building and Building Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'20 years	'	'
Minimum [Member] | Machinery and Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Consolidated [Member]	'	'	'
Ownership Interests [Line Items]	'	'	'
Number Of Centers Owned Less Than 51 Percent	3	'	'
Nonconsolidated [Member]	'	'	'
Ownership Interests [Line Items]	'	'	'
Number Of Centers Owned Less Than 51 Percent	3	'	'
Number Of Centers Owned Greater Than 51 Percent	0	'	'

Acquisitions_and_Investments_i1

Acquisitions and Investments in Unconsolidated Affiliates (Narrative) (Details) (USD $)

12 Months Ended

0 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 01, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Minimum [Member]

Maximum [Member]

Noncontrolling Interest Number Of Centers [Member]

Controlling Interest [Member]

Controlling Interest [Member]

Acquired Nsc Centers [Member]

Acquired Nsc Centers [Member]

Acquired Nsc Centers [Member]

Current Year Acquisitions [Member]

Centers

Centers

Centers

Centers

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Equity Method Investments

$16,392,000

$11,274,000

'

'

'

'

'

'

'

'

'

$5,201,000

Gain (loss) on deconsolidation

2,237,000

0

0

'

'

'

'

'

'

'

'

'

Estimated Probability Of Fair Value Variables Range

'

'

'

5.00%

30.00%

'

'

'

'

'

'

'

Number of Businesses Acquired

'

'

'

'

'

1

5

17

17

'

'

'

Payments to Acquire Businesses, Net of Cash Acquired

73,594,000

277,388,000

239,223,000

'

'

'

'

'

'

'

'

'

Purchase Price Payable Commitment

'

'

'

'

'

'

'

'

'

'

2,744,000

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

'

'

'

'

'

'

'

'

7,500,000

'

'

'

Contingent Purchase Price Obligation, Settlement Amount

2,744,000

'

'

'

'

'

'

'

'

2,744,000

'

'

Goodwill deductible for tax purposes

70,147,000

260,547,000

'

'

'

'

'

'

'

'

'

'

Other operating expenses in acquisition related costs, primarily attorney fees

$300,000

$700,000

'

'

'

'

'

'

'

'

'

'

Acquisitions_Fair_Value_Of_Tot

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'	'
Goodwill	$1,758,970	$1,652,002	$1,229,298
Series of Individually Immaterial Business Acquisitions [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Accounts receivable	4,011	11,572	'
Supplies, inventory, prepaid and other current assets	2,014	4,750	'
Property and equipment	6,894	23,546	'
Goodwill	116,243	429,504	'
Other intangible assets	0	800	'
Accounts payable	-2,214	-3,199	'
Other accrued liabilities	-532	-2,387	'
Long-term debt	-3,028	-6,954	'
Other long-term liabililties	-254	0	'
Total fair value	123,134	457,632	'
Less: Fair value attributable to noncontrolling interests	49,792	182,073	'
Acquisition date fair value of total consideration transferred	$73,342	$275,559	'

Acquisitions_Revs_and_Earnings

Acquisitions (Revs and Earnings) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Net earnings	$71,168	$62,267	$65,836	$62,273	$59,394	$53,765	$55,545	$54,939	$261,544	$223,643	$190,114
Less: Net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	188,841	161,080	140,117
Net earnings (loss) attributable to AmSurg Corp. common shareholders	19,558	16,771	18,563	17,811	16,814	15,437	15,536	14,776	72,703	62,563	49,997
Series of Individually Immaterial Business Acquisitions [Member]	'	'	'	'	'	'	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	15,616	11,247	'
Net earnings	'	'	'	'	'	'	'	'	4,596	3,441	'
Less: Net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	2,603	1,977	'
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	$1,993	$1,464	'

Acquisitions_Consolidated_Pro_

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Acquisitions and Investments in Unconsolidated Affiliates	'	'
Revenues	$1,108,686	$1,116,214
Net earnings	269,903	261,251
Amounts Attributable To Common Shareholders	'	'
Net earnings from continuing operations	75,411	76,893
Net earnings	$75,461	$77,221
Net earnings from continuing operations per common share: Basic	$2.41	$2.50
Net earnings from continuing operations per common share: Diluted	$2.36	$2.43
Net earnings: Basic	$2.41	$2.51
Net earnings: Diluted	$2.36	$2.44
Weighted average number of shares and share equivalents: Basic	31,338	30,773
Weighted average number of shares and share equivalents: Diluted	31,954	31,608

Dispositions_Results_Of_Operat

Dispositions (Results Of Operations Of Centers Discontinued) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Dispositions	'	'	'	'	'	'	'	'	'	'	'
Cash proceeds from disposal	'	'	'	'	'	'	'	'	$3,553	$7,309	$7,026
Net earnings (loss) from discontinued operations	2,800	-295	196	70	2,010	617	4	-410	2,771	2,221	1,820
Net gain (loss) from discontinued operations attributable to AmSurg Corp.	$235	($285)	$74	$26	$1,202	$241	($403)	($712)	$50	$328	($28)

Dispositions_Results_Of_Operat1

Dispositions (Results Of Operations Of Combined Discontinued Surgery Centers) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Dispositions	'	'	'
Revenues	$3,224	$10,975	$18,814
Earnings (loss) before income taxes	227	2,724	4,318
Net earnings (loss)	$169	$2,196	$3,363

Property_and_Equipment_Narrati

Property and Equipment (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment	'	'	'
Capitalized Interest	$24,000	$43,000	$85,000
Unfunded ConstructionAnd Equipment Purchases	953,000	'	'
Depreciation Expense	$32,974,000	$30,072,000	$26,068,000

Property_and_Equipment_PPE_Sch

Property and Equipment (PPE Schedule) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment	'	'
Buildings and improvements	$161,805	$151,270
Movable equipment and software	228,212	208,541
Construction in Progress	2,321	2,313
Property, Plant and Equipment, Gross	392,338	362,124
Less accumulated depreciation	-222,443	-195,512
Property, Plant and Equipment, Net	$169,895	$166,612

Goodwill_And_Intangible_Assets2

Goodwill And Intangible Assets (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill And Intangible Assets	'	'	'
Amortization of Intangible Assets	$2,178,000	$1,415,000	$1,472,000
Deferred Financing Costs, Increase (Decrease)	6,200,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	2,243,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Two	2,242,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Three	2,242,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Four	1,988,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	1,424,000	'	'
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	1,698,000	'	'
Finite-Lived Intangible Asset, Useful Life	'5 years 8 months 12 days	'	'
Restrictive Covenant Agreements	$9,825,000	$9,825,000	'

Goodwill_And_Intangible_Assets3

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill And Intangible Assets	'	'
Balance, beginning of period	$1,652,002	$1,229,298
Goodwill acquired, including post acquisition adjustments	112,951	429,504
Goodwill disposed, including impact of deconsolidation transaction	-5,983	-6,800
Balance, end of period	$1,758,970	$1,652,002

Goodwill_And_Intangible_Assets4

Goodwill And Intangible Assets (Summary Of Amortizable Intangible Assets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$19,262	$17,971
Accumulated Amortization	-7,425	-5,279
Net	11,837	12,692
Deferred financing cost [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	15,814	14,523
Accumulated Amortization	-4,953	-3,029
Net	10,861	11,494
Agreements, contracts and other intangible assets	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	3,448	3,448
Accumulated Amortization	-2,472	-2,250
Net	$976	$1,198

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Line of Credit [Member]	Unsecured Debt [Member]	Secured Debt [Member]	Capital Lease Obligations [Member]	Other Debt Obligations [Member]	Maximum [Member]	Minimum [Member]	Period from current report date to November 30, 2015	Period from January 1, 2012 through November 7, 2012
								Line of Credit [Member]	Line of Credit [Member]	Unsecured Debt [Member]	Secured Debt [Member]
Long-term Debt, by Maturity [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Repayments of Principal in Next Twelve Months	$20,844,000	'	'	'	'	'	'	'	'	'	'
Repayments of Principal after Year Five	272,185,000	'	'	'	'	'	'	'	'	'	'
Long-term Debt, Maturing in Years Two and Three [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Repayments of Principal in Year Two	17,751,000	'	'	'	'	'	'	'	'	'	'
Repayments of Principal in Year Three	14,903,000	'	'	'	'	'	'	'	'	'	'
Long-term Debt, Maturing in Years Four and Five [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Repayments of Principal in Year Four	13,422,000	'	'	'	'	'	'	'	'	'	'
Repayments of Principal in Year Five	265,037,000	'	'	'	'	'	'	'	'	'	'
Credit Facility	'	'	'	'	'	'	'	'	'	'	'
Borrowing capacity of new revolving credit agreement	'	'	475,000,000	'	'	'	'	'	'	'	'
Line of Credit Facility, Expiration Date	'	'	1-Jun-18	'	'	'	'	'	'	'	'
Debt instruments interest rate base rate plus	'	'	'	'	'	'	'	1.00%	0.25%	'	'
Debt instruments interest rate Libor plus	'	'	'	'	'	'	'	2.00%	1.25%	'	'
Unused capacity commitment fee, percentage	'	'	'	'	'	'	'	0.40%	0.25%	'	'
Senior Unsecured Debt	'	'	'	'	'	'	'	'	'	'	'
Unsecured Debt	250,000,000	250,000,000	'	'	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	5.63%	8.04%	'	'	'	'	'	6.04%
Debt Instrument, Maturity Date	'	'	'	30-Nov-20	28-May-20	31-Dec-26	30-Nov-25	'	'	'	'
Redeemable Principal Percentage	'	'	'	35.00%	'	'	'	'	'	'	'
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	'	'	'	'	'	'	'	'	'	105.63%	'
Senior Secured Debt	'	'	'	'	'	'	'	'	'	'	'
Senior Secured Notes	69,643,000	75,000,000	'	'	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	5.63%	8.04%	'	'	'	'	'	6.04%
Debt Instrument, Maturity Date	'	'	'	30-Nov-20	28-May-20	31-Dec-26	30-Nov-25	'	'	'	'
Debt Instrument, Interest Rate Increase	'	'	'	'	2.00%	'	'	'	'	'	'
Other Long-term Debt [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Book Value of Collateralized By Certain Assets	'	'	'	'	'	'	$74,150,000	'	'	'	'

LongTerm_Debt_Components_Of_Lo

Long-Term Debt (Components Of Long-Term Debt) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Long-Term Debt	'	'
Revolving credit agreement	$252,500	$279,780
Senior Unsecured Notes	250,000	250,000
Senior Secured Notes	69,643	75,000
Other debt	21,149	21,350
Capitalized lease arrangements	10,850	11,982
Long-term debt, gross	$604,142	$638,112

Long_Term_Debt_Current_Noncurr

Long Term Debt (Current & Noncurrent Breakout) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Long-term Debt, Current and Noncurrent [Abstract]	'	'
Long-term debt	$583,298	$620,705
Less current portion	20,844	17,407
Long-term debt, gross	$604,142	$638,112

Long_Term_Debt_Parenthetical_D

Long Term Debt (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2013
Line of Credit [Member]	'
Debt Instrument [Line Items]	'
Long-term Debt, Weighted Average Interest Rate	2.10%
Unsecured Debt [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Maturity Date	30-Nov-20
Debt Instrument, Interest Rate, Stated Percentage	5.63%
Secured Debt [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Maturity Date	28-May-20
Debt Instrument, Interest Rate, Stated Percentage	8.04%
Capital Lease Obligations [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Maturity Date	31-Dec-26
Long-term Debt, Weighted Average Interest Rate	5.30%
Other Debt Obligations [Member]	'
Debt Instrument [Line Items]	'
Debt Instrument, Maturity Date	30-Nov-25
Long-term Debt, Weighted Average Interest Rate	3.60%

LongTerm_Debt_Redemption_Price

Long-Term Debt (Redemption Price) (Details) (Unsecured Debt [Member])	Dec. 31, 2013
Period from November 30, 2015 to November 29, 2016	'
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	104.22%
Period from November 30, 2016 to November 29, 2017	'
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	102.81%
Period from November 30, 2017 to November 29, 2018	'
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	101.41%
Period from November 30, 2018 to November 30, 2020	'
Future Redemption Price of Debt During Eligibility Period, as a Percentage of Principal Amount	100.00%

Derivative_Instruments_Narrati

Derivative Instruments (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Apr. 30, 2011
Derivative Instruments	'	'	'	'
Derivative, Notional Amount	'	'	'	$50,000,000
Percentage of interest rate swap pays to counterparty	'	'	'	5.37%
Unrealized gain on interest rate swap, net of income tax	$0	$0	$515,000	'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements	'	'
Business Acquisition, Preacquisition Contingency, Amount of Settlement	$2,744,000	'
Debt Instrument [Line Items]	'	'
Long-term Debt gross	604,142,000	638,112,000
Fixed Interest Rate [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt gross	348,958,000	354,105,000
Long-term Debt, Fair Value	364,349,000	379,036,000
Variable Interest Rate [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt gross	255,184,000	284,007,000
Long-term Debt, Fair Value	$255,184,000	$284,007,000

Fair_Value_Measurements_Fair_V

Fair Value Measurements (Fair Value Of Assets And Liabilities Measured On A Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 2 [Member]	'	'
Supplemental executive retirement savings plan investments - Level 2	$13,313	$8,804
Fair Value, Inputs, Level 3 [Member]	'	'
Contingent purchase price payable - Level 3	$0	$2,744

Leases_Narrative_Details

Leases (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Leases	'	'	'
Lease Expiration Date	31-Dec-33	'	'
Capital Leased Assets, Gross	$13,950,000	'	'
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation	3,635,000	'	'
Operating Leases, Rent Expense, Net	$52,641,000	$47,278,000	$42,413,000

Leases_Future_Min_Schedule_Det

Leases (Future Min Schedule) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Leases	'	'
Capital Leases, Future Minimum Payments Due, Current	$2,040	'
Capital Leases, Future Minimum Payments Due in Two Years	1,673	'
Capital Leases, Future Minimum Payments Due in Three Years	1,404	'
Capital Leases, Future Minimum Payments Due in Four Years	1,184	'
Capital Leases, Future Minimum Payments Due in Five Years	1,000	'
Capital Leases, Future Minimum Payments Due Thereafter	7,003	'
Total minimum rentals	14,304	'
Less amounts representing interest	3,454	'
Capital Lease Obligations, Total	10,850	11,982
Operating Leases, Future Minimum Payments Due, Current	47,704	'
Operating Leases, Future Minimum Payments, Due in Two Years	46,557	'
Operating Leases, Future Minimum Payments, Due in Three Years	45,772	'
Operating Leases, Future Minimum Payments, Due in Four Years	45,174	'
Operating Leases, Future Minimum Payments, Due in Five Years	43,718	'
Operating Leases, Future Minimum Payments, Due Thereafter	354,087	'
Total minimum rentals	$583,012	'

Leases_Parenthetical_Details

Leases (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2013
Maximum [Member]	'
Capital Lease Interest Rate Range [Line Items]	'
Capital Lease Interest Rates	11.80%
Minimum [Member]	'
Capital Lease Interest Rate Range [Line Items]	'
Capital Lease Interest Rates	2.90%

Shareholders_Equity_Narrative_

Shareholder's Equity (Narrative) (Details) (USD $)	0 Months Ended		12 Months Ended
	Aug. 09, 2013	Apr. 24, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	M	M
Common Stock:	'	'	'	'	'
Stock repurchased program authorized by the board of directors	$40,000,000	$40,000,000	'	'	'
Period of stock repurchase program, months	18	18	'	'	'
Average price per share	'	'	$36.93	$28.50	'
Amount remaining under stock repurchase plan	'	'	27,100,000	'	'
Stock Incentive Plans:	'	'	'	'	'
Unrecognized compensation cost on non vested awards	'	'	7,426,000	'	'
Employee Service Share-based Compensation, Nonvested Awards	'	'	'1 year 0 months 0 days	'	'
Share based payment award shares purchased for award	'	'	0	20,000	923,000
Stock Repurchased Under Repurchase Program [Member]	'	'	'	'	'
Common Stock:	'	'	'	'	'
Repurchase of common stock, shares	'	'	1,154,378	415,084	'
Repurchase of common stock	'	'	42,652,000	11,838,000	'
Stock Repurchased To Cover Employee Tax Withholdings [Member]	'	'	'	'	'
Common Stock:	'	'	'	'	'
Repurchase of common stock, shares	'	'	102,252	48,139	'
Repurchase of common stock	'	'	$3,312,000	$1,263,000	'
Outside Directors [Member]	'	'	'	'	'
Stock Incentive Plans:	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'1 year	'1 year	'
Employees [Member]	'	'	'	'	'
Stock Incentive Plans:	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'4 years	'	'
Number of installments in restricted stock granted.	'	'	3	'	'
Options term	'	'	10	'	'
Stock Options [Member]	'	'	'	'	'
Stock Incentive Plans:	'	'	'	'	'
Number of shares authorized for grant under share incentive plan	'	'	2,760,250	'	'
Shares available for future grants/issuance under stock incentive plan	'	'	895,822	'	'
Restricted Stock [Member]	'	'	'	'	'
Stock Incentive Plans:	'	'	'	'	'
Shares available for future grants/issuance under stock incentive plan	'	'	733,718	'	'

Shareholders_Equity_ShareBased

Shareholders' Equity (Share-Based Activity) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Shareholders' Equity	'	'	'
Share-based compensation expense	$8,321	$6,692	$6,178
Fair value of shares vested	11,742	6,425	7,356
Cash received from option exercises	33,349	18,214	6,872
Tax benefit from option exercises	$7,247	$1,784	$977

Shareholders_Equity_Schedule_O

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Shareholders' Equity	'	'	'
Non-vested shares at beginning of period, Number of Shares	828,686	732,412	664,909
Shares granted, Number of Shares	291,863	281,429	276,869
Shares vested, Number of Shares	-360,337	-183,019	-208,949
Shares forfeited, Number of Shares	-16,343	-2,136	-417
Non-vested shares at end of period, Number of Shares	743,869	828,686	732,412
Non-vested shares at beginning of period, Weighted Average Grant Price	$22.50	$21.91	$22.16
Shares granted, Weighted Average Grant Price	$31.66	$26.78	$21.78
Shares vested, Weighted Average Grant Price	$21.55	$25.98	$23.11
Shares forfeited, Weighted Average Grant Price	$23.11	$26.26	$24.75
Non-vested shares at end of period, Weighted Average Grant Price	$26.54	$22.50	$21.91

Recovered_Sheet1

Shareholder's Equity (Schedule of Stock Option Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Shareholders' Equity	'	'	'	'
Outstanding at beginning of period, Number of Shares	1,662,830	2,510,054	2,901,989	'
Options exercised, Number of Shares	-1,392,366	-841,599	-374,350	'
Options terminated, Number of Shares	'	-5,625	-17,585	'
Outstanding at end of period, Number of Shares	270,464	1,662,830	2,510,054	2,901,989
Vested or expected to vest at end of period, Number of Shares	270,464	'	'	'
Exercisable at end of period, Number of Shares	270,464	'	'	'
Outstanding at beginning of period, Weighted Average Exercise Price	$23.82	$23.09	$22.49	'
Options exercised, Weighted Average Grant Price	$23.95	$21.64	$18.36	'
Options terminated, Weighted Average Grant Price	'	$21.85	$25.42	'
Outstanding at end of period, Weighted Average Exercise Price	$23.16	$23.82	$23.09	$22.49
Vested or expected to vest at end of period, Weighted Average Exercise Price price	$23.16	'	'	'
Exercisable at end of period, Weighted Average Exercise Price	$23.16	'	'	'
Weighted Average Remaining Contractual Term, Period Start	'2 years 6 months 0 days	'2 years 10 months 24 days	'3 years 4 months 24 days	'4 years 6 months 0 days
Weighted Average Remaining Contractual Term, Period End	'2 years 6 months 0 days	'2 years 10 months 24 days	'3 years 4 months 24 days	'4 years 6 months 0 days
Weighted Average Remaining Contractual Term, Vested or expected to vest	'2 years 6 months 0 days	'	'	'
Weighted Average Remaining Contractual Term, Exercisable	'2 years 6 months 0 days	'	'	'

Shareholders_Equity_Schedule_o1

Shareholder's Equity (Schedule of Stock Option Activity (Parenthetical) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Shareholders' Equity	'	'	'
Total intrinsic value with options exercised	$33,349,000	$6,287,000	$2,482,000
Aggregate intrinsic value of options outstanding	6,156,000	'	'
Total intrinsic value of options vested or expected to vest	6,156,000	'	'
Total intrinsic value of options exercisable	$6,156,000	'	'

Recovered_Sheet2

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Shareholders' Equity	'	'	'	'	'	'	'	'	'	'	'
Net earnings from continuing operations attributable to AmSurg Corp., Earnings (Numerator)	$19,323	$17,056	$18,489	$17,785	$15,612	$15,196	$15,939	$15,488	$72,653	$62,235	$50,025
Net earnings attributable to AmSurg Corp., Earnings (Numerator)	$19,558	$16,771	$18,563	$17,811	$16,814	$15,437	$15,536	$14,776	$72,703	$62,563	$49,997
Net earnings from continuing operations attributable to AmSurg Corp. (Basic), Shares (Denominator)	'	'	'	'	'	'	'	'	31,338	30,773	30,452
Effect of dilutive securities options and non-vested shares	'	'	'	'	'	'	'	'	616	835	759
Net earnings from continuing operations attributable to AmSurg Corp. (Diluted), Shares (Denominator)	'	'	'	'	'	'	'	'	31,954	31,608	31,211
Net earnings from continuing operations attributable to AmSurg Corp. per common share (Basic), Per Share Amount	'	'	'	'	'	'	'	'	$2.32	$2.02	$1.64
Net earnings from continuing operations attributable to AmSurg Corp. per common share (Diluted), Per Share Amount	$0.60	$0.53	$0.58	$0.56	$0.49	$0.48	$0.50	$0.49	$2.27	$1.97	$1.60
Net earnings attributable to AmSurg Corp. per common share (Basic), Per Share Amount	'	'	'	'	'	'	'	'	$2.32	$2.03	$1.64
Net earnings attributable to AmSurg Corp. per common share (Diluted), Per Share Amount	$0.61	$0.52	$0.58	$0.56	$0.53	$0.49	$0.49	$0.47	$2.28	$1.98	$1.60

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes	'	'	'
Change in interest related to unrecognized tax benefits	($189,000)	($132,000)	($109,000)
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	943,000	1,132,000	'
Unrecognized Tax Benefits, Income Tax Penalties Expense	0	0	0
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$150,000	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Operating Loss Carryforwards, Expiration Dates	31-Dec-14	'	'
State and Local Jurisdiction [Member]	'	'	'
Operating Loss Carryforwards [Line Items]	'	'	'
Operating Loss Carryforwards, Expiration Dates	31-Dec-15	'	'

Income_Taxes_Total_Income_Tax_

Income Taxes (Total Income Tax Expense) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Taxes	'	'	'
Income from continuing operations	$49,754	$42,364	$34,973
Discontinued operations	-1,091	1,574	3,032
Shareholders' equity	-7,381	-1,581	-649
Other comprehensive income	0	0	332
Total	$41,282	$42,357	$37,688

Income_Taxes_Income_Tax_Expens

Income Taxes (Income Tax Expense from Cont. Ops) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	$8,437	$15,326	$11,671
State	3,724	4,974	3,541
Deferred:	'	'	'
Federal	31,909	18,488	17,502
State	5,684	3,576	2,259
Income tax expense	$49,754	$42,364	$34,973

Income_Taxes_Income_Tax_Expens1

Income Taxes (Income Tax Expense Reconciliation to Federal Rate) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]	'	'	'
Statutory federal income tax	$107,984	$92,325	$78,143
Less federal income tax assumed directly by noncontrolling interests	-65,142	-55,715	-48,394
State income taxes, net of federal income tax benefit	5,539	5,309	3,642
Increase in valuation allowances	924	419	1,622
Interest related to unrecognized tax benefits	-155	-109	-83
Other	604	135	43
Income tax expense	$49,754	$42,364	$34,973

Income_Taxes_Unrecognized_Tax_

Income Taxes (Unrecognized Tax Liability Rec) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Balance at beginning of year	$9,235	$7,252	$7,144
Additions for tax positions of current year	46	119	342
Increases for tax positions taken during a prior period	0	1,985	'
Decreases for tax positions taken during a prior period	'	'	-190
Lapse of statute of limitations	-2,951	-121	-44
Balance at end of year	$6,330	$9,235	$7,252

Income_Taxes_Deferred_Assets_a

Income Taxes (Deferred Assets and Liabilities) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Taxes Assets [Abstract]	'	'
Allowance for uncollectible accounts	$897	$884
Accrued assets and other	5,292	5,212
Valuation allowances	-2,021	-2,084
Total current deferred tax assets	4,168	4,012
Share-based compensation	7,635	9,500
Interest on unrecognized tax benefits	230	363
Accrued liabilities and other	3,629	3,077
Operating and capital loss carryforwards	9,185	9,169
Valuation allowances	-7,665	-7,265
Total non-current deferred tax assets	13,014	14,844
Total deferred tax assets	17,182	18,856
Deferred Tax Liabilities [Abstract]	'	'
Prepaid expenses	1,071	925
Property and equipment, principally due to differences in depreciation	4,137	3,997
Goodwill, principally due to differences in amortization	184,897	148,494
Total deferred tax liabilities	190,105	153,416
Total deferred tax liabilities	$172,923	$134,560

Income_Taxes_Deferred_Tax_Liab

Income Taxes (Deferred Tax Liability Schedule) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Deferred Tax Assets (Liabilities), Net [Abstract]	'	'
Current deferred income tax assets	$3,097	$3,088
Deferred income taxes	176,020	137,648
Total deferred tax liabilities	$172,923	$134,560

Related_Party_Transactions_Rel

Related Party Transactions (Related Party Payments) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Related Party Transactions	'	'	'
Operating leases	$29,240	$29,079	$29,137
Salaries and benefits	72,892	65,908	64,830
Billing fees	11,591	11,126	11,240
Medical advisory services	$2,993	$2,671	$2,575

Employee_Benefit_Programs_Deta

Employee Benefit Programs (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]	'	'	'
SERP contribution	$2,338,000	$1,693,000	$915,000
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'	'	'
Employer contributions	$1,095,000	$1,031,000	$594,000
Board of Director's [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]	'	'	'
SERP contribution percentage	100.00%	'	'
Officer's [Member]	'	'	'
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]	'	'	'
SERP contribution percentage	50.00%	'	'
SERP Vesting Period	'5	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Y
Business Combination, Contingent Consideration Arrangements [Abstract]	'
Contractual Obligation Term	15
Contractual Obligation Lease Square Footage	110,000
Contractual Obligation Annual Rental Payment	$2,300,000
Contractual Obligation Annual Rental Payment Increase	1.90%
Contractual Obligation Maximum Tenant Allowance	$4,400,000

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Summary Of Supplemental Cash Flow Information) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash Paid During The Period For	'	'	'
Interest	$28,378	$14,786	$13,815
Income taxes, net of refunds	7,756	19,615	10,232
Noncash Investing and Financing Activities	'	'	'
Increase (decrease) in accounts payable associated with acquisition of property and equipment	884	248	659
Capital lease obligations	$738	$1,096	$466

Guarantor_Balance_Sheets_Detai

Guarantor (Balance Sheets) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Assets	'	'	'	'
Cash and cash equivalents	$50,840,000	$46,398,000	$40,718,000	$34,147,000
Accounts receivable, net	105,072,000	96,752,000	'	'
Supplies inventory	18,414,000	18,406,000	'	'
Deferred income taxes	3,097,000	3,088,000	'	'
Prepaid and other current assets	33,602,000	27,537,000	'	'
Total current assets	211,025,000	192,181,000	'	'
Property and equipment, net	169,895,000	166,612,000	'	'
Investments in unconsolidated affiliates and long-term notes receivable	16,392,000	11,274,000	'	'
Total assets	2,177,944,000	2,044,586,000	'	'
Liabilities and Equity	'	'	'	'
Current portion of long-term debt	20,844,000	17,407,000	'	'
Accounts payable	27,501,000	23,509,000	'	'
Total current liabilities	89,870,000	84,413,000	'	'
Long-term debt	583,298,000	620,705,000	'	'
Deferred income taxes	176,020,000	137,648,000	'	'
Other long-term liabilities	25,503,000	25,972,000	'	'
Noncontrolling interests - redeemable	177,697,000	175,382,000	'	'
Equity:	'	'	'	'
Total AmSurg Corp. equity	764,197,000	689,488,000	'	'
Noncontrolling interests - non-redeemable	361,359,000	310,978,000	'	'
Total equity	1,125,556,000	1,000,466,000	'	'
Total liabilities and equity	2,177,944,000	2,044,586,000	'	'
Consolidation, Eliminations [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	'	'
Supplies inventory	0	0	'	'
Deferred income taxes	0	0	'	'
Prepaid and other current assets	-4,362,000	-4,965,000	'	'
Total current assets	-4,362,000	-4,965,000	'	'
Property and equipment, net	0	0	'	'
Investments in unconsolidated affiliates and long-term notes receivable	-2,922,178,000	-2,783,383,000	'	'
Goodwill and other intangible assets, net	1,758,970,000	1,652,002,000	'	'
Total assets	-1,167,570,000	-1,136,346,000	'	'
Liabilities and Equity	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	-3,958,000	-3,905,000	'	'
Other accrued liabilities	-404,000	-1,060,000	'	'
Total current liabilities	-4,362,000	-4,965,000	'	'
Long-term debt	-31,377,000	-31,465,000	'	'
Deferred income taxes	0	0	'	'
Other long-term liabilities	0	0	'	'
Noncontrolling interests - redeemable	113,993,000	113,443,000	'	'
Equity:	'	'	'	'
Total AmSurg Corp. equity	-1,568,267,000	-1,490,008,000	'	'
Noncontrolling interests - non-redeemable	322,443,000	276,649,000	'	'
Total equity	-1,245,824,000	-1,213,359,000	'	'
Total liabilities and equity	-1,167,570,000	-1,136,346,000	'	'
Parent Company [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents	6,710,000	7,259,000	8,530,000	4,683,000
Accounts receivable, net	0	0	'	'
Supplies inventory	33,000	0	'	'
Deferred income taxes	3,097,000	3,088,000	'	'
Prepaid and other current assets	23,993,000	19,342,000	'	'
Total current assets	33,833,000	29,689,000	'	'
Property and equipment, net	9,829,000	9,199,000	'	'
Investments in unconsolidated affiliates and long-term notes receivable	1,484,974,000	1,413,061,000	'	'
Goodwill and other intangible assets, net	20,684,000	21,311,000	'	'
Total assets	1,549,320,000	1,473,260,000	'	'
Liabilities and Equity	'	'	'	'
Current portion of long-term debt	10,714,000	5,357,000	'	'
Accounts payable	1,972,000	1,379,000	'	'
Other accrued liabilities	27,419,000	29,380,000	'	'
Total current liabilities	40,105,000	36,116,000	'	'
Long-term debt	561,429,000	599,423,000	'	'
Deferred income taxes	176,020,000	137,648,000	'	'
Other long-term liabilities	7,569,000	10,585,000	'	'
Noncontrolling interests - redeemable	0	0	'	'
Equity:	'	'	'	'
Total AmSurg Corp. equity	764,197,000	689,488,000	'	'
Noncontrolling interests - non-redeemable	0	0	'	'
Total equity	764,197,000	689,488,000	'	'
Total liabilities and equity	1,549,320,000	1,473,260,000	'	'
Guarantor Subsidiaries [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	0	0	'	'
Supplies inventory	0	0	'	'
Deferred income taxes	0	0	'	'
Prepaid and other current assets	0	0	'	'
Total current assets	0	0	'	'
Property and equipment, net	0	0	'	'
Investments in unconsolidated affiliates and long-term notes receivable	1,453,596,000	1,381,596,000	'	'
Goodwill and other intangible assets, net	0	0	'	'
Total assets	1,453,596,000	1,381,596,000	'	'
Liabilities and Equity	'	'	'	'
Current portion of long-term debt	0	0	'	'
Accounts payable	0	0	'	'
Other accrued liabilities	0	0	'	'
Total current liabilities	0	0	'	'
Long-term debt	0	0	'	'
Deferred income taxes	0	0	'	'
Other long-term liabilities	0	0	'	'
Noncontrolling interests - redeemable	0	0	'	'
Equity:	'	'	'	'
Total AmSurg Corp. equity	1,453,596,000	1,381,596,000	'	'
Noncontrolling interests - non-redeemable	0	0	'	'
Total equity	1,453,596,000	1,381,596,000	'	'
Total liabilities and equity	1,453,596,000	1,381,596,000	'	'
Non-Guarantor Subsidiaries [Member]	'	'	'	'
Assets	'	'	'	'
Cash and cash equivalents	44,130,000	39,139,000	32,188,000	29,464,000
Accounts receivable, net	105,072,000	96,752,000	'	'
Supplies inventory	18,381,000	18,406,000	'	'
Deferred income taxes	0	0	'	'
Prepaid and other current assets	13,971,000	13,160,000	'	'
Total current assets	181,554,000	167,457,000	'	'
Property and equipment, net	160,066,000	157,413,000	'	'
Investments in unconsolidated affiliates and long-term notes receivable	0	0	'	'
Goodwill and other intangible assets, net	978,000	1,206,000	'	'
Total assets	342,598,000	326,076,000	'	'
Liabilities and Equity	'	'	'	'
Current portion of long-term debt	10,130,000	12,050,000	'	'
Accounts payable	29,487,000	26,035,000	'	'
Other accrued liabilities	14,510,000	15,177,000	'	'
Total current liabilities	54,127,000	53,262,000	'	'
Long-term debt	53,246,000	52,747,000	'	'
Deferred income taxes	0	0	'	'
Other long-term liabilities	17,934,000	15,387,000	'	'
Noncontrolling interests - redeemable	63,704,000	61,939,000	'	'
Equity:	'	'	'	'
Total AmSurg Corp. equity	114,671,000	108,412,000	'	'
Noncontrolling interests - non-redeemable	38,916,000	34,329,000	'	'
Total equity	153,587,000	142,741,000	'	'
Total liabilities and equity	342,598,000	326,076,000	'	'
Consolidated Entities [Member]	'	'	'	'
Assets	'	'	'	'
Goodwill and other intangible assets, net	1,780,632,000	1,674,519,000	'	'
Liabilities and Equity	'	'	'	'
Accounts payable	27,501,000	23,509,000	'	'
Other accrued liabilities	$41,525,000	$43,497,000	'	'

Guarantor_Income_Statements_De

Guarantor (Income Statements) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$284,570	$267,631	$268,099	$259,043	$242,775	$223,885	$228,955	$227,567	$1,079,343	$923,182	$772,075
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Salaries and benefits	'	'	'	'	'	'	'	'	333,190	290,063	238,738
Supply cost	'	'	'	'	'	'	'	'	157,771	131,055	101,364
Other operating expenses	'	'	'	'	'	'	'	'	222,677	193,025	168,347
Depreciation and amortization	'	'	'	'	'	'	'	'	33,028	29,850	25,645
Total operating expenses	'	'	'	'	'	'	'	'	746,666	643,993	534,094
Gain (loss) on deconsolidation	'	'	'	'	'	'	'	'	2,237	0	0
Equity in earnings of unconsolidated affiliates	'	'	'	'	'	'	'	'	3,151	1,564	613
Operating income	'	'	'	'	'	'	'	'	338,065	280,753	238,594
Interest expense	'	'	'	'	'	'	'	'	29,538	16,967	15,327
Earnings from continuing operations before income taxes	81,644	73,989	78,398	74,496	67,854	63,211	66,611	66,110	308,527	263,786	223,267
Income tax expense	'	'	'	'	'	'	'	'	49,754	42,364	34,973
Net earnings from continuing operations	68,368	62,562	65,640	62,203	57,384	53,148	55,541	55,349	258,773	221,422	188,294
Net earnings (loss) from discontinued operations	2,800	-295	196	70	2,010	617	4	-410	2,771	2,221	1,820
Net earnings (loss)	71,168	62,267	65,836	62,273	59,394	53,765	55,545	54,939	261,544	223,643	190,114
Less net earnings attributable to noncontrolling interests:	'	'	'	'	'	'	'	'	'	'	'
Net earnings from continuing operations	'	'	'	'	'	'	'	'	186,120	159,187	138,269
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	2,721	1,893	1,848
Total net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	188,841	161,080	140,117
Net earnings (loss) attributable to AmSurg Corp. common shareholders	19,558	16,771	18,563	17,811	16,814	15,437	15,536	14,776	72,703	62,563	49,997
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of income tax	19,323	17,056	18,489	17,785	15,612	15,196	15,939	15,488	72,653	62,235	50,025
Discontinued operations, net of income tax	235	-285	74	26	1,202	241	-403	-712	50	328	-28
Net earnings (loss) attributable to AmSurg Corp. common shareholders	19,558	16,771	18,563	17,811	16,814	15,437	15,536	14,776	72,703	62,563	49,997
Other comprehensive income, net of income tax:	'	'	'	'	'	'	'	'	'	'	'
Unrealized gain on interest rate swap, net of income tax	'	'	'	'	'	'	'	'	0	0	515
Comprehensive income, net of income tax	'	'	'	'	'	'	'	'	261,544	223,643	190,629
Less comprehensive income attributable to noncontrolling interests	'	'	'	'	'	'	'	'	188,841	161,080	140,117
Comprehensive income attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	72,703	62,563	50,512
Consolidation, Eliminations [Member]	'	'	'	'	'	'	'	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	-17,518	-14,901	-8,001
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Salaries and benefits	'	'	'	'	'	'	'	'	-467	-450	-359
Supply cost	'	'	'	'	'	'	'	'	0	0	0
Other operating expenses	'	'	'	'	'	'	'	'	-17,051	-14,451	-7,642
Depreciation and amortization	'	'	'	'	'	'	'	'	0	0	0
Total operating expenses	'	'	'	'	'	'	'	'	-17,518	-14,901	-8,001
Gain (loss) on deconsolidation	'	'	'	'	'	'	'	'	-2,237	'	'
Equity in earnings of unconsolidated affiliates	'	'	'	'	'	'	'	'	-406,773	-354,710	-304,205
Operating income	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Interest expense	'	'	'	'	'	'	'	'	0	0	0
Earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Income tax expense	'	'	'	'	'	'	'	'	0	0	0
Net earnings from continuing operations	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss)	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Less net earnings attributable to noncontrolling interests:	'	'	'	'	'	'	'	'	'	'	'
Net earnings from continuing operations	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	0	0	0
Total net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of income tax	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Discontinued operations, net of income tax	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Other comprehensive income, net of income tax:	'	'	'	'	'	'	'	'	'	'	'
Unrealized gain on interest rate swap, net of income tax	'	'	'	'	'	'	'	'	'	'	0
Comprehensive income, net of income tax	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Less comprehensive income attributable to noncontrolling interests	'	'	'	'	'	'	'	'	0	0	0
Comprehensive income attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	-409,010	-354,710	-304,205
Parent Company [Member]	'	'	'	'	'	'	'	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	24,167	19,907	11,253
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Salaries and benefits	'	'	'	'	'	'	'	'	61,038	54,895	42,739
Supply cost	'	'	'	'	'	'	'	'	0	0	0
Other operating expenses	'	'	'	'	'	'	'	'	22,660	20,499	19,468
Depreciation and amortization	'	'	'	'	'	'	'	'	3,186	2,860	2,487
Total operating expenses	'	'	'	'	'	'	'	'	86,884	78,254	64,694
Gain (loss) on deconsolidation	'	'	'	'	'	'	'	'	2,237	'	'
Equity in earnings of unconsolidated affiliates	'	'	'	'	'	'	'	'	204,962	178,137	152,409
Operating income	'	'	'	'	'	'	'	'	144,482	119,790	98,968
Interest expense	'	'	'	'	'	'	'	'	27,282	14,803	13,195
Earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	117,200	104,987	85,773
Income tax expense	'	'	'	'	'	'	'	'	48,239	40,810	33,806
Net earnings from continuing operations	'	'	'	'	'	'	'	'	68,961	64,177	51,967
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	3,742	-1,614	-1,970
Net earnings (loss)	'	'	'	'	'	'	'	'	72,703	62,563	49,997
Less net earnings attributable to noncontrolling interests:	'	'	'	'	'	'	'	'	'	'	'
Net earnings from continuing operations	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	0	0	0
Total net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	72,703	62,563	49,997
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of income tax	'	'	'	'	'	'	'	'	68,961	64,177	51,967
Discontinued operations, net of income tax	'	'	'	'	'	'	'	'	3,742	-1,614	-1,970
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	72,703	62,563	49,997
Other comprehensive income, net of income tax:	'	'	'	'	'	'	'	'	'	'	'
Unrealized gain on interest rate swap, net of income tax	'	'	'	'	'	'	'	'	'	'	515
Comprehensive income, net of income tax	'	'	'	'	'	'	'	'	72,703	62,563	50,512
Less comprehensive income attributable to noncontrolling interests	'	'	'	'	'	'	'	'	0	0	0
Comprehensive income attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	72,703	62,563	50,512
Guarantor Subsidiaries [Member]	'	'	'	'	'	'	'	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	0	0	0
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Salaries and benefits	'	'	'	'	'	'	'	'	0	0	0
Supply cost	'	'	'	'	'	'	'	'	0	0	0
Other operating expenses	'	'	'	'	'	'	'	'	0	0	0
Depreciation and amortization	'	'	'	'	'	'	'	'	0	0	0
Total operating expenses	'	'	'	'	'	'	'	'	0	0	0
Gain (loss) on deconsolidation	'	'	'	'	'	'	'	'	2,237	'	'
Equity in earnings of unconsolidated affiliates	'	'	'	'	'	'	'	'	204,962	178,137	152,409
Operating income	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Interest expense	'	'	'	'	'	'	'	'	0	0	0
Earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Income tax expense	'	'	'	'	'	'	'	'	0	0	0
Net earnings from continuing operations	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss)	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Less net earnings attributable to noncontrolling interests:	'	'	'	'	'	'	'	'	'	'	'
Net earnings from continuing operations	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	0	0	0
Total net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of income tax	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Discontinued operations, net of income tax	'	'	'	'	'	'	'	'	0	0	0
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Other comprehensive income, net of income tax:	'	'	'	'	'	'	'	'	'	'	'
Unrealized gain on interest rate swap, net of income tax	'	'	'	'	'	'	'	'	'	'	0
Comprehensive income, net of income tax	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Less comprehensive income attributable to noncontrolling interests	'	'	'	'	'	'	'	'	0	0	0
Comprehensive income attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	207,199	178,137	152,409
Non-Guarantor Subsidiaries [Member]	'	'	'	'	'	'	'	'	'	'	'
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	1,072,694	918,176	768,823
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Salaries and benefits	'	'	'	'	'	'	'	'	272,619	235,618	196,358
Supply cost	'	'	'	'	'	'	'	'	157,771	131,055	101,364
Other operating expenses	'	'	'	'	'	'	'	'	217,068	186,977	156,521
Depreciation and amortization	'	'	'	'	'	'	'	'	29,842	26,990	23,158
Total operating expenses	'	'	'	'	'	'	'	'	677,300	580,640	477,401
Gain (loss) on deconsolidation	'	'	'	'	'	'	'	'	0	'	'
Equity in earnings of unconsolidated affiliates	'	'	'	'	'	'	'	'	0	0	0
Operating income	'	'	'	'	'	'	'	'	395,394	337,536	291,422
Interest expense	'	'	'	'	'	'	'	'	2,256	2,164	2,132
Earnings from continuing operations before income taxes	'	'	'	'	'	'	'	'	393,138	335,372	289,290
Income tax expense	'	'	'	'	'	'	'	'	1,515	1,554	1,167
Net earnings from continuing operations	'	'	'	'	'	'	'	'	391,623	333,818	288,123
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	-971	3,835	3,790
Net earnings (loss)	'	'	'	'	'	'	'	'	390,652	337,653	291,913
Less net earnings attributable to noncontrolling interests:	'	'	'	'	'	'	'	'	'	'	'
Net earnings from continuing operations	'	'	'	'	'	'	'	'	186,120	159,187	138,269
Net earnings (loss) from discontinued operations	'	'	'	'	'	'	'	'	2,721	1,893	1,848
Total net earnings attributable to noncontrolling interests	'	'	'	'	'	'	'	'	188,841	161,080	140,117
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	201,811	176,573	151,796
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of income tax	'	'	'	'	'	'	'	'	205,503	174,631	149,854
Discontinued operations, net of income tax	'	'	'	'	'	'	'	'	-3,692	1,942	1,942
Net earnings (loss) attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	201,811	176,573	151,796
Other comprehensive income, net of income tax:	'	'	'	'	'	'	'	'	'	'	'
Unrealized gain on interest rate swap, net of income tax	'	'	'	'	'	'	'	'	'	'	0
Comprehensive income, net of income tax	'	'	'	'	'	'	'	'	390,652	337,653	291,913
Less comprehensive income attributable to noncontrolling interests	'	'	'	'	'	'	'	'	188,841	161,080	140,117
Comprehensive income attributable to AmSurg Corp. common shareholders	'	'	'	'	'	'	'	'	$201,811	$176,573	$151,796

Guarantor_Cash_Flow_Statements

Guarantor (Cash Flow Statements) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net cash flows provided by operating activities	$332,824	$295,652	$243,423
Cash flows from investing activities:	'	'	'
Acquisition of interests in surgery centers and related transactions	-73,594	-277,388	-239,223
Acquisition of property and equipment	-28,856	-28,864	-22,170
Proceeds from sale of interests in surgery centers	3,553	7,309	7,026
Other	159	0	0
Net cash flows used in investing activities	-98,738	-298,943	-254,367
Cash flows from financing activities:	'	'	'
Proceeds from long-term borrowings	162,204	565,566	288,869
Repayment on long-term borrowings	-202,083	-394,164	-129,107
Distributions to noncontrolling interests	-184,149	-162,941	-138,724
Net cash flows provided by (used in) financing activities	-229,644	8,971	17,515
Net increase (decrease) in cash and cash equivalents	4,442	5,680	6,571
Cash and cash equivalents, beginning of year	46,398	40,718	34,147
Cash and cash equivalents, end of year	50,840	46,398	40,718
Consolidation, Eliminations [Member]	'	'	'
Cash flows from operating activities:	'	'	'
Net cash flows provided by operating activities	-347,648	-182,851	-151,558
Cash flows from investing activities:	'	'	'
Acquisition of interests in surgery centers and related transactions	694	92,830	88,803
Acquisition of property and equipment	0	0	0
Proceeds from sale of interests in surgery centers	0	0	0
Other	0	'	'
Net cash flows used in investing activities	694	92,830	88,803
Cash flows from financing activities:	'	'	'
Proceeds from long-term borrowings	0	0	0
Repayment on long-term borrowings	0	0	0
Distributions to noncontrolling interests	347,648	182,851	151,558
Capital contributions	'	-90,029	-84,597
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	-694	-2,801	-4,206
Net cash flows provided by (used in) financing activities	346,954	90,021	62,755
Net increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents, beginning of year	0	0	0
Cash and cash equivalents, end of year	0	0	0
Parent Company [Member]	'	'	'
Cash flows from operating activities:	'	'	'
Net cash flows provided by operating activities	45,127	-83,605	-67,911
Cash flows from investing activities:	'	'	'
Acquisition of interests in surgery centers and related transactions	0	-90,029	-84,597
Acquisition of property and equipment	-3,693	-3,681	-2,858
Proceeds from sale of interests in surgery centers	0	0	0
Other	0	'	'
Net cash flows used in investing activities	-3,693	-93,710	-87,455
Cash flows from financing activities:	'	'	'
Proceeds from long-term borrowings	152,700	560,000	281,100
Repayment on long-term borrowings	-188,081	-381,220	-118,100
Distributions to noncontrolling interests	0	0	0
Capital contributions	'	0	0
Changes in intercompany balances with affiliates, net	88	-2,666	-178
Other financing activities, net	-6,690	-70	-3,609
Net cash flows provided by (used in) financing activities	-41,983	176,044	159,213
Net increase (decrease) in cash and cash equivalents	-549	-1,271	3,847
Cash and cash equivalents, beginning of year	7,259	8,530	4,683
Cash and cash equivalents, end of year	6,710	7,259	8,530
Guarantor Subsidiaries [Member]	'	'	'
Cash flows from operating activities:	'	'	'
Net cash flows provided by operating activities	208,773	182,851	151,558
Cash flows from investing activities:	'	'	'
Acquisition of interests in surgery centers and related transactions	-74,288	-280,189	-243,429
Acquisition of property and equipment	0	0	0
Proceeds from sale of interests in surgery centers	3,553	7,309	7,274
Other	159	'	'
Net cash flows used in investing activities	-70,576	-272,880	-236,155
Cash flows from financing activities:	'	'	'
Proceeds from long-term borrowings	0	0	0
Repayment on long-term borrowings	0	0	0
Distributions to noncontrolling interests	-138,875	0	0
Capital contributions	'	90,029	84,597
Changes in intercompany balances with affiliates, net	0	0	0
Other financing activities, net	678	0	0
Net cash flows provided by (used in) financing activities	-138,197	90,029	84,597
Net increase (decrease) in cash and cash equivalents	0	0	0
Cash and cash equivalents, beginning of year	0	0	0
Cash and cash equivalents, end of year	0	0	0
Non-Guarantor Subsidiaries [Member]	'	'	'
Cash flows from operating activities:	'	'	'
Net cash flows provided by operating activities	426,572	379,257	311,334
Cash flows from investing activities:	'	'	'
Acquisition of interests in surgery centers and related transactions	0	0	0
Acquisition of property and equipment	-25,163	-25,183	-19,312
Proceeds from sale of interests in surgery centers	0	0	-248
Other	0	'	'
Net cash flows used in investing activities	-25,163	-25,183	-19,560
Cash flows from financing activities:	'	'	'
Proceeds from long-term borrowings	9,504	5,566	7,769
Repayment on long-term borrowings	-14,002	-12,944	-11,007
Distributions to noncontrolling interests	-392,922	-345,792	-290,282
Capital contributions	'	0	0
Changes in intercompany balances with affiliates, net	-88	2,666	178
Other financing activities, net	1,090	3,381	4,292
Net cash flows provided by (used in) financing activities	-396,418	-347,123	-289,050
Net increase (decrease) in cash and cash equivalents	4,991	6,951	2,724
Cash and cash equivalents, beginning of year	39,139	32,188	29,464
Cash and cash equivalents, end of year	44,130	39,139	32,188
Consolidated Entities [Member]	'	'	'
Cash flows from financing activities:	'	'	'
Other financing activities, net	($5,616)	$510	($3,523)

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Centers
Aggregate purchase price of surgery centers	$5,100,000
Number of business units	1

Quarterly_Financial_Data_Unaud2

Quarterly Financial Data Unaudited (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Data Abstract	'	'	'	'	'	'	'	'	'	'	'
Revenues	$284,570	$267,631	$268,099	$259,043	$242,775	$223,885	$228,955	$227,567	$1,079,343	$923,182	$772,075
Earnings from continuing operations before income taxes	81,644	73,989	78,398	74,496	67,854	63,211	66,611	66,110	308,527	263,786	223,267
Net earnings from continuing operations	68,368	62,562	65,640	62,203	57,384	53,148	55,541	55,349	258,773	221,422	188,294
Net earnings (loss) from discontinued operations	2,800	-295	196	70	2,010	617	4	-410	2,771	2,221	1,820
Net earnings	71,168	62,267	65,836	62,273	59,394	53,765	55,545	54,939	261,544	223,643	190,114
Amounts attributable to AmSurg Corp. common shareholders:	'	'	'	'	'	'	'	'	'	'	'
Earnings from continuing operations, net of income tax	19,323	17,056	18,489	17,785	15,612	15,196	15,939	15,488	72,653	62,235	50,025
Discontinued operations, net of income tax	235	-285	74	26	1,202	241	-403	-712	50	328	-28
Net earnings (loss) attributable to AmSurg Corp. common shareholders	$19,558	$16,771	$18,563	$17,811	$16,814	$15,437	$15,536	$14,776	$72,703	$62,563	$49,997
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders	$0.60	$0.53	$0.58	$0.56	$0.49	$0.48	$0.50	$0.49	$2.27	$1.97	$1.60
Net earnings attributable to AmSurg Corp. common shareholders	$0.61	$0.52	$0.58	$0.56	$0.53	$0.49	$0.49	$0.47	$2.28	$1.98	$1.60

Schedule_II_Valuation_and_Qual2

Schedule II Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts [Member]	'	'	'
Valuation and Qualifying Accounts Disclosure [Line Items]	'	'	'
Valuation Allowances and Reserves, Balance, Beginning Balance	$22,379	$18,844	$13,070
Charged to Cost and Expenses	21,983	20,340	18,501
Charged to Other Accounts	6,410	4,561	3,967
Charge-off Against Allowances	-22,910	-21,366	-16,694
Valuation Allowances and Reserves, Balance, Ending Balance	$27,862	$22,379	$18,844